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Abstract  
Coagulation is the process responsible for the transformation of blood into a solid mass 
formed by fibrin, platelet and blood cell, namely clot. The normal functioning of this 
process named Homeostasis produces the repair of an injury. 
Disorders of coagulation can lead to an increased risk of obstructive clotting (thrombosis), 
that is, in severe cases, lethal for the organism. 
Despite its phenomenal success, current anticoagulation therapy still suffers from the risk 
toward serious bleeding. A direct correlation exists between the intensity of 
anticoagulation and severity of bleeding. The need for safer and more effective 
antithrombotic agents clearly exists. During the last twenty years, aptamer technology is 
efficiently employed toward the development of therapeutic anticoagulants, by selecting 
thrombin-binding-oligonucleotides. The term aptamers is generally referred to single-
stranded oligonucleotides that bind to a selected protein and specifically inhibits one or 
more of its functions.  
The TBA (Thrombin-Binding-Aptamer), isolated via SELEX , is a 15-nucleotide consensus 
sequence that binds thrombin and inhibits its coagulant activity. TBA adopts a 
monomolecular chair-like G-quadruplex structure consisting of two G-tetrads connected by 
two lateral TT and a central TGT loops. Biological and structural results indicate that TBA 
exerts its anticoagulant activity competing with fibrinogen at the exosite I on the thrombin. 
Despite an high number of scientific results concerning the structure and the biological 
properties of TBA and its analogues were published during the last years, today still, the 
exact mechanism of action by which TBA exerts its antithrombin activity is an open 
question.  
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In the frame of different multidisciplinary studies, I synthesized and I characterized for 
their tridimensional structures as well as for their biological behavior, different libraries of 
new TBA analogues, with the aim to acquire new information about the differences in the 
mechanism of action of TBA and its synthetic analogues.  
Furthermore, since TBA is a very promising tool for DNA-functionalized biosensors, I also 
synthesized new heterochiral TBA mutants with the aim to make stable the phosphodiester 
bonds of this molecule in biological environment. These new molecules were studied for 
their ability to fold in stable G-quadruplexes using different spectroscopic techniques.   
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1.THROMBIN 
Thrombin is a serine-protease playing a key role in blood coagulation.1 In mammalian, 
the equilibrium between the production and the inhibition of this enzyme, prevents 
the occurrence of hemorrhagic or thrombotic pathologies. The importance of 
thrombin is, beside of its unique enzymatic activity towards fibrinogen, the ability to 
catalyze many other coagulation-related reactions (Figure 1). It is now clear that 
thrombin, because of allosteric mechanism, is responsible for both procoagulant and 
anticoagulant stimuli by interaction with several substrates.2 In presence of 
procoagulant stimuli3,4 thrombin activates itself, factor V and factor XIII; the latter is a 
fibrin-ligase which makes strong the bonds between fibrin molecules. Furthermore, 
thrombin hydrolyzes the N-terminal extracellular domain of a membrane receptor 
named PAR-1 (type 1 Protease Activated Receptor, belonging from the G proteins-
coupled super family receptors) which promotes platelet activation. All procoagulant 
stimuli ultimate into the conversion of soluble fibrinogen into insoluble fibrin. 
However, at the starting point of procoagulant stimuli thrombin and its glycoprotein 
co-factors must be produced. In the whole process (the coagulative cascade) a series 
of reactions promote the conversion of the zymogens (inactive enzyme precursors) in 
to active proteases, which, in turn, catalyze the next reaction in the cascade. The 
contemporary starting up of fibrinogen and PAR receptors by thrombin, leads to the 
formation of the platelet plug. Furthermore, thrombin is able to self-generate, through 
an activation of the feedback type, mediated by zymogen factor XI5 and cofactors V 
and VII.6,7 Thrombin also activates the transglutaminase Factor XIIIa, that, in 
turn,catalyzes the formation of covalent bonds between the fibrin fibers, stabilizing 
the clot.8 Finally, it seems to have an important role in the cleavage of the von 
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Willebrand factor. This is a large multimeric glycoprotein(2050 aa., 250 kDa) present in 
blood plasma and is produced constitutively as ultra-large vWF in endothelium (in the 
Weibel-Palade bodies), megakaryocytes (α-granules of platelets), and subendothelial 
connective tissue. It recruits and activates platelets and is deficient in an inherited 
bleeding disorder called von Willebrand disease.9 
 
Figure 1.The network of thrombin. 
In presence of anticoagulant stimuli, thrombin binds to thrombomodulin, a membrane 
receptor present on endothelial cells and activates protein C.10 The binding of 
thrombomodulin suppresses the ability of thrombin to cleave fibrinogen, but enhances 
1,000-fold the specificity of the enzyme toward the zymogen protein C. Activated 
protein C cleaves and inactivates factors Va and VIIIa, two essential cofactors of 
coagulation, factors Xa and IXa that are required for thrombin generation, thereby 
down-regulating both the amplification and the progression of the coagulation 
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cascade. Thrombin is finally inhibited and cleared from the circulation by circulating 
serpins AT and HCII, in a GAG-dependent fashion. 
1.1 Structure of Thrombin 
Singular structural features of thrombin determinates the regulation of its multiple 
functions.11 In 1989, Bode et al. published the X-ray structure of thrombin. The same 
group reported a refined crystal in 1992.12,13 Because of thrombin belongs to the 
chymotrypsin family, the numbering of its substrates is based on the Schechter and 
Berger nomenclature, in which substrate residues are numbered from the scissile P1-
P1’ bond toward the N- and C-termini, respectively.14 
Thrombin consists of two disulfide-linked polypeptide chains that are folded into a 
trypsin-like protease. The A chain is composed of 36 residues and is non-essential for 
proteolytic activities. The B chain is composed of 259 amino acids and is derived from 
the carboxyl terminal sequence of prothrombin (Figure 2). Thrombin is trypsin-like, 
since it prefers to cleave its substrates after arginine residues. Like trypsin, the 
thrombin B chain contains the active site residues Ser195, His57, and Asp102, but also 
contains insertion loops that extend around the active site cleft, making it deeper and 
more narrow than that of trypsin. This insertion loops are known as the 60 and -
insertion loops. The 60-loop is composed of Leu60, Tyr60a, Pro60b, Pro60c, Trp60d, 
Asp60e,Lys60f, Asn60g, Phe60h, and Thr60i, with Asn60g glycosylated. It is evident 
from the sequence that the 60-loop is hydrophobic in nature, with the two consecutive 
prolines serving to rigidify. 
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Figure 2. Structure of thrombin bound to the active site inhibitor PPACK (stick model) and Na+ 
(ball). The A chain runs in the back of the B chain. Disulfide bonds are numbered 1 (C1–C122),2 
(C48–C52), 3 (C168–C182), 4 (C191–C220). Relevant domains are noted. Catalytic residues 
(H57, D102, S195) are marked by asterisk, and D189 is labeled. The bound Na + is nestled 
between the 220-loop and the 186-loop and is within 5 Å from the side chain of D189. 
Numbering refers to chymotrypsin(ogen) (see Color Plates) [from Thrombin: physiology and 
disease. 2009. Chapter 1: Thrombin: Structure, Functions and Regulation, pagg 1-18 ]  
 
The 60-loop, thus provides a rigid, hydrophobic cap over the active site and mediates 
contacts with the hydrophobic substrate residues N-terminal to the scissile bond. In 
contrast, the -loop is more hydrophilic and flexible in nature; composed of Thr147, 
Trp147a, Thr147b,Ala147c, Asn147d, and Val147f. It is often incompletely modeled in 
crystal structures due to its inherent mobility, but, as it is adjacent to the active site 
cleft of thrombin, it can contact substrate residues C-terminal to the scissile bond, and 
can make contacts with the body of substrate proteins. In forming the active site, the 
loops also serve to restrict access to the catalytic domain of thrombin to proteins with 
long, flexible substrate loops, or to proteins with complementary surfaces which 
mediate contact with the loops. In addition to these two insertions, the area also 
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includes access to the active site residue Glu192, whose negative charge plays an 
important role in discriminating substrates containing acid residues in the proximity of 
the scissile peptide bond (i.e. in the case of the binding to protein C orto receptor I of 
thrombin). In the active site there is another important zone, the Na+ binding site that 
was first identified crystallographically in 1995.15 Na+ binds 16–20 Å away from 
residues of the catalytic triad and within 5 Å from D189 in the S1 site, nestled between 
the 220- and 186-loops and coordinated octahedrally by two carbonyl O atoms from 
the protein (residues R221a and K224) and four buried water molecules. 
Unlike trypsin, thrombin, has extra surface structures that influence the interactions 
with macromolecular substrates and thus make it a more discriminating protease. One 
of these subsites is called the anion-binding exosite-1 (ABE-1) that is adjacent to the P’ 
side of active site cleft. It contains residues from the Arg67 to the Glu80, Arg35, 
Lys149e, Lys81, Lys110, Lys109, and Lys36. Thrombin ABE-1 has been implicated in 
binding of fibrinogen, hirudin, and heparin cofactor II. Another surface structure of 
thrombin is called the anion-binding exosite-2 (ABE-2), that is primarily responsible for 
the ability of thrombin to bind glycosaminoglycan. Furthermore, the region from 
Leu144 to Gly150 forms an additional surface subsite, that contributes to the 
interaction of thrombin with hirudin and thrombomodulin.  
Thrombin specificity can thus be understood as a competition for three sites: the 
active site and exosites I and II. Structural biology has revealed important information 
on how thrombin utilizes both the active site and exosites for interaction with 
substrates, inhibitors, and effectors.2,16,17 
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1.2 Thrombin Substrates  
A lot of studies conducted on thrombin mutants highlighted that the binding of natural 
substrates and cofactors to thrombin require one or both anion binding exosites. 
Among the cofactors of thrombin there is glycoprotein Ibα. It is present on the platelet 
membrane and is important for three actions: platelet aggregation18, activation of 
factor XI19 and cleavage of glycoprotein V.20,21 The interaction of glycoprotein Ibα with 
thrombin occurs between a negatively charged region of the glycoprotein and the 
exosite II of thrombin. There are mainly electrostatic interactions and hydrogen bonds. 
In particular, there is a contact between Arg 233 from exosite II and several oxygen 
atoms of Tyr sulfate 276, 278 and 279,22 which forms the negatively charged region of 
glycoprotein. The exclusive involvement of exosite II has been demonstrated by 
mutagenesis studies:23,24 thrombin variants having mutated residues in the exosite II 
showed reduced binding affinity for the glycoprotein Ibα respect to wild-type protein, 
while similar modifications involving exosite I had no effects on the binding affinity. 
Fibrinogen, the principal protein of vertebrate blood clotting, is an hexamer, 
containing two sets of three different chains (α, β, and ), which are joined each-other 
in the N-terminal E domain by ﬁve symmetrical disulﬁde bridges25 (Figure 3). Thrombin 
converts the soluble fibrinogen into insoluble fibrin strands. These strands are then 
cross-linked by factor XIIIa to form stable blood clot. Fibrinogen is a substrate whose 
recognition by thrombin is directly mediated by active site and exosite I interactions to 
form a Michaelis complex, defined by a Km in the micromolar range. Thrombin residues 
seen in direct contact with fibrin were F34, S36a, L65, Y76, R77a, I82, and K110. 
Although the interface interposes the basic exosite I of thrombin with an acidic surface 
of fibrin, the majority of the contacts, and presumably the major energetic 
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contribution, derive from the opposition of hydrophobic surfaces on the two 
molecules (F34, L65, Y76 andI82 on thrombin and F35 and A68 on the A and B 
chains of fibrin, respectively).26 
The high binding affinity suggests that thrombin-fibrin interactions also involves 
thrombin exosite II. In particular the C-terminal of the ' fibrin chain, which contains 
negatively charged residues, contributes to the binding of fibrin on thrombin exosite II. 
 
 
 
Figure 3. Schematic diagram of fibrinogen structure, its conversion to fibrin, and the thrombin-
mediated conversion of native factor XIII to XIIIa. Binding sites for proteins, enzymes, receptors, 
and other molecules that participate in fibrin(ogen) functions are illustrated. [from Journal of 
Thrombosis and Haemostasis, 2005, 3, 1894–1904] 
 
Another important cofactor is thrombomodulin27 (TM), that is expressed on the 
surface of endothelial cells. It is a single chain glycoprotein that participates in the 
activation of protein C which, in turn , inactivates factors V and VIII. It is composed of 
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five regions: (1) the N-terminal lectin-like domain; (2) six consecutive EGF-like repeats; 
(3) a proteoglycan-like Ser-Thr-rich region which is highly O-glycosylated; (4) a single 
transmembrane helix; and, (5) the C-terminal cytoplasmic tail. The thrombomodulin 
binds mainly exosite I by hydrophobic contacts between isoleucine 414 and 424 of 
thrombomodulin and leucine 65 of thrombin. The replacement of isoleucine with 
alanine 37 reduces the binding efficiency and shows the importance of this 
hydrophobic contact.28 However, chondroitinsulfate (CS) moiety, found on about 20% 
of TM molecules in the vascular endothelium and about 30%–35% of those lining the 
arteries, improves the affinity of TM for thrombin by an order-of-magnitude.29 
In the final phase thrombin is inhibited by serpins and cofactor II. Serpins are inhibitors 
of serine proteases and are activated by heparin-like glycosaminoglycans (GAGs) such 
as heparan sulfate, chondroitin sulfate and dermatan sulfate, that are long chain 
polysaccharides able to bind thrombin and to accelerate 1000 folds its inhibition by 
serpins.30,31 Heparin and dermatan sulfate also accelerate the thrombin inhibition 
mediated by heparin cofactor II. Several studies have shown that the heparin-binding 
site of thrombin was localized in the exosite II. The heparin-thrombin interaction is 
ionic in nature and involves the negatively charged sulfate groups of heparin and 
several positively charged residues of thrombin represented by basic amino acids. The 
Arg 93 is responsible for 3 ionic interactions with the oxygens of the sulphate, the Lys 
236 participates in two interactions. The Arg 101 and 233 have only one interaction. 
The Lys 240 provides probably other three interactions and finally, the His 230 
determines the formation of an hydrogen bond. Five heparin residues are sufficient to 
achieve the right length for the complete occupation of thrombin binding 
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site.32However, to inhibit thrombin heparin must be formed at least by 18 saccharide 
residues, since single molecule of heparin binds to both thrombin and serpin.33 
Monovalent cation sodium (Na+) is an important cofactor able to modulate thrombin 
activity. It coordinates the carbonyl oxygens of Arg 221a and Lys 224 and 4 water 
molecules in a octahedral geometry (Figure 4). The presence of Na+influences the 
thrombin conformations.34,35 It has been suggested that the enzyme can exist in two 
forms named "fast" and "slow". In the form bonded to Na+, thrombin assumes the 
"fast" conformation and activates PAR-1 and fibrinogen, there by playing the pro-
coagulant action. In contrast, without Na+, thrombin loses affinity for the pro-
coagulant factors but activates protein C. 
 
 
Figure 4.The Na+ binding site of thrombin representation. 
 
It is evident that, during the hemostatic process, thrombin binds a large number of 
cofactors. Initially thrombin binds species that induce pro-coagulant stimuli promoting 
the formation of the platelet plug. After its formation, fibrin acts as a cofactor for 
thrombin-activated, factor XIII and all substrates with anticoagulant activity. This 
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points out that the efficiency of the coagulation cascade depends on the balance 
between the procoagulant and anticoagulant pathways, and the thrombin together its 
ligands are the key arbiter of this balance. 
 
1.3 Thrombin allostery 
The ability of thrombin to adopt pro-coagulant and anti-coagulant form, known as the 
"paradox of thrombin”, suggests the hypothesis of an allosteric modulation of the 
protein functions. 
Protein allostery36,37 is based on the existence of equilibria between multiple 
conformations, each of them linked to distinct functional properties. The allosteric 
regulation of a protein starts with the formation of a complex protein-effector, in 
which the enzyme assumes a slightly modified tertiary structure. This new structure 
can have modified affinity for other substrates, and, consequently, can influences the 
catalytic activity of the enzyme. Effectors that enhance the protein activity are referred 
to as allosteric activators, whereas those that decrease the protein activity are called 
allosteric inhibitors. Generally, the regulatory site of an allosteric protein is physically 
distinct from its active site. The original studies concerning the molecular allosteric 
mechanism of multimeric proteins were been performed by Perutz.38 For such 
systems, the conformational transitions influence the quaternary structure and 
allostery features have been detected crystallographically. One of the most popular 
allosteric protein is Hemoglobin. The binding of O2 to one hemoglobin subunit induces 
conformational changes that are relayed to the other subunits, making them more 
able to bind to O2 by raising their affinity for this molecule. In particular, after binding 
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of O2, the proximal histidine(F8) moving toward heme pocket, triggers structural 
changes that alter the interaction between the α and β chains, leading to the transition 
from T to R form. T or "stretched" state, represents the conformation having low 
oxygen affinity, while the R or "released" state is the high oxygen affinity one. The 
allostery, however, is not exclusive of multimeric assemblies; in fact, many monomeric 
proteins, such as thrombin, show a remarkable structural plasticity, attributable to the 
existence of an allosteric modulation of their functions.39-41 
As described in the section 1.2 thrombin utilizes exosites I and/or II in the molecular 
events that modulate its functions. Although X-ray data indicate that some substrates 
are able to bind both exosites, several different studies support absolute exosite 
discrimination. Such experimental and theoretical analyses1 indicate that hydrophobic 
contacts provide the majority of the binding energy for exosite I interactions, while the 
electrostatic contacts in this site seem to have the role of orientate the 
complementary hydrophobic surfaces (so-called electrostatic steering). Exosite II 
interactions, on the other hand, are primarily ionic in nature, with hydrophobics 
contributing minimally to the overall binding energy1. On these basis it has been 
proposed to call, most properly,exosite I ”the apolar-binding exosite”, and exosite II 
“the anion-binding exosite”. 
The concept of thrombin allostery is based on the effects produced by interaction of 
ligand on exosite I or II. These exosites facilitate the binding of substrates or cofactors 
and align them for optimal interaction with the active site42. 
Currently, there are two different theories to recognize the thrombin allostery. 
According to Di Cera et al.41,43different thrombin conformations are related to the 
presence of cation sodium. Recently, some studies insert thrombin allostery in a 
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continuum balancing of different stimuli that convert the enzyme in zymogen-like or 
protease-like form.44  
 
1.3.1 Effects of Thrombin-Na+ interaction 
Di Cera et al. consider two thrombin conformations named “slow” and “fast” 
respectively, in reference to rate of proteolysis fibrinogen reaction.45The allosteric 
transition is regulated by interaction with the Na+ ion, which binds to 15 Å away from 
the active site residues, stabilizing the pro-coagulant form (fast) (Figure 5). Under 
physiological conditions, the Kd of thrombin for Na
+ ions has a value (110 mM) very 
closed to the Na+ blood concentration (145 mM) .46-50Thus, fast and slow thrombin 
forms are almost equally populated in vivo (ratio 3:2, respectively) and the binding of 
specific cofactors can shift the equilibrium towards the slow (such as the anticoagulant 
heparin) or the fast form (such as the pro-coagulant fibrin).34The slow form, called E, 
accounts for 40% of the molecules in vivo, on the contrary the fast form,also called 
E:Na+, represents approximately 60% of the molecules in vivo. However, there seems 
to be a third conformation named E* (about 1% of the molecules in vivo), that is in 
equilibrium with E, unable to bind sodium, defined E* or “inactive conformation” of 
thrombin. Therefore, the Na+-free thrombin can be divided in two conformations, E 
and E*, which only E is able to interact with sodium. A large number of spectroscopic 
and mutagenesis studies support the following transitions between the different 
forms: the transition from E to E:Na+ induces a global change involving the nine Trp 
residues of thrombin, located up to 35 Å from sodium binding site; the second, from E* 
to E, concerns the whole enzyme structure.51 The X-ray structure of a complex 
between a thrombin mutant (D102N) and a peptide fragment of the PAR 1 was 
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published.52 The thrombin mutant D102N is stabilized in a self-inhibited conformation 
where the access to the active site is occluded by a collapse of the entire 215–219 -
strand. This study proves that, the binding of a fragment of PAR1 to D102N-exosite I, 
occurring 30-Å away from the active site region, causes a large conformational change 
that corrects the position of the 215–219 -strand and restores the access to the active 
site. These conformational changes of the mutant protein, as well as other 
experimental data, has been understood by Di Cera et al. through the Na+allosteric 
regulation of thrombin; in fact: 
1. no conformational changes occurred upon the formation of native protein-PAR1 
complex; 
2. exosite I-PAR3 interaction53-57 induced relevant conformational changes. This 
disturbance consists in the moving of the indole ring of Trp 60 and in the upward 
movement of the loop 60, thus allowing thrombomodulin to fulfill the function of 
cofactor. In fact, the exosite I -TM binding fully opens the active site by increasing 
the rate of diffusion of protein C.58,59 This conformational change can be deleted in 
the presence of an active site inhibitor; 
3. no changing/disruption of thrombin conformation follows the ligand contacts with 
exosite I, such as the case of the binding of hirugen, a deca-peptide derived from 
the C-terminal fragment of hirudin. The hirugen-thrombin, as well as 
thrombomodulin-thrombin complex has just slight differences in the active 
site,compared to free-thrombin.60 
According to Di Cera et al., the influences of exosite I ligands on thrombin can be 
explained taking into account the three forms of enzyme: E* , E and E: Na+. The binding 
of PAR 1 fragment to the exosite I of the E:Na+ form causes only a shift of 60-loop that 
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opens the active site. On the contrary, the same ligand can generate an extensive 
conformational transition of the E*form, as in the case of the mutant D102N. The 
conformational transition results in a long-range communication of exosite I and the 
opposite site of thrombin, nearly to 30 Å distant. 
Finally, the E form can be achieved by the binding of the PAR-3 to the exosite I, that 
allows to anticoagulant effects. 
 
 
Figure 5. Schematic representation of the multiple roles of thrombin inthe blood and how Na+ 
binding influences them.The fast form is responsible for the efficient cleavage offibrinogen 
leading to clot formation, and activation of factors V, VIIIand XI that promote the progression 
of the coagulation response tovascular injury. The fast form is also responsible for the 
activation ofPAR1, PAR3 and PAR4 leading to platelet activation and cellsignaling. The slow 
form, on the other hand, activates efficiently theanticoagulant protein C with the assistance of 
the cofactor thrombomodulin. Na+ binding to thrombin is the major driving force behindthe 
procoagulant, prothrombotic and signaling roles of the enzyme inthe blood, but is not required 
for its anticoagulant role triggered byprotein C activation. Any effect that destabilizes Na+ 
binding producesan anticoagulant effect by shifting thrombin to the slow form. 
[from Phys. Chem. Chem. Phys., 2007, 9, 1292–1306] 
 
 
17 
 
1.3.2 Zymogen-like and Proteinase-like states of Thrombin 
The alternative theory to explain allosteric thrombin phenomena came from other 
works which consider zymogen-like and proteinase-like species of thrombin. 
Thrombin is produced by proteolytic activation of the precursor, prothrombin, in the 
first step of the coagulation pathway. After proteolysis, the transition of zymogen to 
proteinase is not obvious, since thrombin can reversibly interconvert between 
zymogen- and proteinase-like forms, depending on the binding of complementary 
ligands. 
According to supporters of this theory, the understanding of thrombin allostery 
requires knowledge about the equilibria involved in proteinase generation (thrombin) 
from its zymogen form (prothrombin), because the thrombin regulation is in 
continuum with thrombin generation.61 
 
 
Figure 6. Pathways for the Proteolytic Conversion of Prothrombin to Thrombin. 
[from Journal of Thrombosis and Haemostasis, 11 (Suppl. 1): 265–276] 
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There are two pathways for the proteolytic conversion of Prothrombin to Thrombin 
(Figure 6). The conversion of prothrombin to thrombin results from cleavages 
following Arg271 and Arg320. Initial cleavage following Arg271 yields the pathway on 
the left and produces the zymogen, prethrombin 2 (P2) and the propiece, fragment 1.2 
(F12) as intermediates. P2 requires further processing at Arg320 to yield thrombin. 
The pathway on the right arises from initial cleavage following Arg320, which produces 
the proteinase meizothrombin (mIIa) as an intermediate. Further cleavage following 
Arg271 is required to yield thrombin (IIa) and the propiece, F12. The Arg155 site (Red 
Arrow) is susceptible to thrombin cleavage and separates the fragment 1 region from 
fragment2 within F12. 
Isothermal titration calorimetric experiments highlighted substantial differences in 
affinity and energetics between the binding of F12 to thrombin and to the P2 
zymogen.62  
Profound differences in H and S with modest changes in G were observed for the 
binding of F12 to P2, a cleaved but zymogen-like form of thrombin, the catalytically 
inactive variant of thrombin containing Ser195 substituted with Ala and thrombin 
covalently stabilized in the most proteinase-like form by covalent modiﬁcation with 
FPRck. Large compensating changes in H and S for F12 binding were observed as the 
species increasingly became proteinase-like and were consistent with the binding of 
the propiece to structurally related zymogen- and proteinase-like forms expected to be 
in reversible equilibrium with each other. Accordingly, high concentrations of an 
active-site-directed ligand could transition the zymogen-like form of thrombin along 
this thermodynamic trajectory to resemble FPR-thrombin.63 Conversely, removal of 
Na+ at constant ionic strength could transition the thermodynamic constants along the 
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same trajectory until binding resembled that seen with the cleaved by zymogen like 
form of thrombin.63 Finally ligands directed towards anion binding exosite 1 (ABE1) 
could favor proteinase-like forms.64 In the extreme, uncleaved P2 could be imbued 
with catalytic activity in the absence of cleavage by strong ligand binding. These points 
illustrate that thrombin occupies a continuum of zymogen-like and proteinase-like 
forms following initial cleavage. The continuum and associated thermodynamic 
compensation in F12 binding derives from the fact that the series of changes 
associated with proteinase maturation following cleavage are additive. These ideas are 
surprising when taken in the context of the irreversibility of peptide bond hydrolysis 
but are in line with the ﬁndings with factor VIIa.65 
The previously reported data on mutant inactive thrombin (see section 3.1.1) can be 
reinterpreted considering every mutation that destabilizes the status proteinase-like 
affects this equilibrium and encourages the zymogen-like form. 
Ligand-dependent interconversions of cleaved thrombin between zymogen- and 
proteinase-like forms can formally be considered by a two-state model although 
multiple sub-states of thrombin are likely involved (Figure. 7).  
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Figure 7. Ligand-Dependent Interconversions of Thrombin Between Zymogen- and Proteinase-
Like Forms. [from Journal of Thrombosis and Haemostasis, 11 (Suppl.1):265–276] 
 
The reasoning behind this model lies in the fact that anion binding exosite 2 (ABE2), to 
which F12 binds, is properly configured in the zymogen-like form but distorted in the 
proteinase-like form. 
In fact, the thrombomodulin binds ABE1 shifting the balance towards the proteinase-
like form and activating protein C.66-67The two species were found to be approximately 
equally populated and the distribution between the two forms could be altered 
predictably by thrombomodulin or by decreasing Na+. 
The Na+ enhances the binding of the hirugen or the thrombomodulin to thrombin. 
These results are in agreement with the fact that both the Na+, and ABE1 ligands 
energetically favor the protease-like form as documented by NMR studies.68 
The binding of F12 to ABE2 favors the zymogen-like form and it is opposed to the 
binding of thrombomodulin-hirugen toABE1. Consequently, the F12-ABE2 binding has 
a negative effect on exosite I ligands and vice versa. 
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Other findings with thrombin imply that mIIa would be exceptionally zymogen-
like.69 Indeed, rapid kinetic studies revealed the slow equilibration of mIIa 
between zymogen-like and proteinase-like forms, only the latter of which could 
bind active-site ligands with high affinity. Single turnover rapid kinetic studies 
revealed that initial cleavage at Arg320 by prothrombinase yields a zymogen-like 
form of mIIa that only slowly equilibrates with the proteinase-like species. 69 
 
 
 
Figure 8. A New Rate-Limiting Step in the Conversion of Prothrombin to Thrombin. Initial 
cleavage of prothrombin following Arg320 yields a zymogen-like form (mIIa’) that interconverts 
slowly and reversibly with the proteinase-like form (mIIa). Because the proteinase-like 
conformation is required for further cleavage at Arg271, it is only mIIa rather than mIIa’ that is 
processed to thrombin. The reversible conversion of mIIa’ to mIIa there represents a previously 
unanticipated rate-limiting step in thrombin formation. [from Journal of Thrombosis and 
Haemostasis, 11 (Suppl. 1): 265–276] 
 
Because of the essential role of the zymogen to proteinase transition in facilitating the 
second cleavage reaction by prothrombinase to yield thrombin, this slow reversible 
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interconversion of mIIa between the two forms describes the ratcheting step proposed 
to separate the two half-reactions of prothrombin activation by prothrombinase.  
 
1.3.3. Long range communication between exosite I and II 
Although exosites 1 and 2 regulate thrombin activity by binding substrates and 
cofactors and by allosterically modulating the active site, it is still unclear whether 
there is direct allosteric linkage between the two exosites. 
To address this, a thrombin variant fluorescently labeled at exosite 1 was titrated with 
exosite 2 ligands, HD22 (a DNA aptamer), γ’-peptide (analog of the COOH terminus of 
the γ’-chain of fibrinogen) or heparin C oncentration-dependent and saturable 
changes in fluorescence were elicited, supporting inter-exosite linkage.70 
To explore the functional consequences of these phenomena, the capacity of exosite 2 
ligands to inhibit thrombin binding to A/A-fibrin, an interaction mediated solely by 
exosite 1 was evaluated. When A/A-fibrinogen was clotted with thrombin in the 
presence of HD22,γ’-peptide, or prothrombin fragment 2 there was a dose-dependent 
and saturable decreasing in thrombin binding to the resultant fibrin clots. 
Furthermore, HD22 reduced the affinity of thrombin for A/A-fibrin 6-fold and 
accelerated the dissociation of thrombin from preformed A/A-fibrin clots. Similar 
responses were obtained when surface plasmon resonance was used to monitor the 
interaction of thrombin with A/A-fibrinogen or fibrin. There is bi-directional 
communication between the exosites, because exosite 1 ligands, HD1 (a DNAaptamer) 
or hirugen (an analog of the COOH terminus of hirudin), inhibited the exosite 2-
mediated interaction of thrombin with immobilized γ’-peptide. These findings provide 
evidence for long range allosteric linkage between exosites 1 and 2 on thrombin, 
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revealing further complexity of thrombin regulation. However it is also unclear 
whether the allosteric connection between the exosites has physiological relevance. 70 
1.4 Thrombin and anticoagulant therapy 
Currently, in anticoagulant therapy were considered molecules that are able to 
influence exosite-active site interaction exclusively. There are heparinoids, which assist 
antithrombin in the inhibition of thrombin and factor Xa. 
Nature has engineered two distinct mechanisms for heparin-activated antithrombin 
inhibition of factor Xa and thrombin. The interaction of high-affinity heparin, or 
pentasaccharide H5, expels the partially inserted RCL residues thereby significantly 
changing the conformation of the P1-P10 reactive center and exposing an exosite in 
antithrombin (Figure 9). 71-74 This phenomenon is called the conformational activation 
of antithrombin. The altered RCL in heparin-antithrombin co-complex is better 
recognized by factor Xa resulting in accelerated cleavage of the P1-P10 bond and rapid 
formation of the covalent inhibited complex (E*-AT*). Thus, conformational activation 
of antithrombin is necessary and sufficient for accelerated factor Xa inhibition. 
Thrombin inhibition, in contrast, is accelerated only two fold through the 
conformational activation mechanism.30 The predominant effect of heparin in 
accelerating thrombin inhibition arises from a bridging mechanism. Tight binding of 
antithrombin to the H5 sequence in full length heparin is followed by the binding of 
thrombin to the same chain at non-specific sites to form an antithrombin–heparin–
thrombin ternary complex. Thrombin then diffuses along the polyanionic chain to 
encounter the inhibitor resulting in a 2,000-fold acceleration in inhibition under 
physiological conditions. A saccharide length of 18 residues is needed to 
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simultaneously hold thrombin and antithrombin for the accelerated inhibition.75,76 
Thus, while sequence-specific H5 is necessary for tight binding of heparin chains, H5 
alone cannot potentiate antithrombin inhibition of thrombin. 
 
 
Figure 9. Mechanism of antithrombin inhibition of factor Xa and thrombin in the presence of 
full-length heparin. An antithrombin- heparin complex (AT:H) is formed following an interaction 
of the high-affinity pentasaccharide sequence (H5) in heparin with the pentasaccharide-binding 
site (PBS).This causes expulsion of the reactive center loop (RCL) that better recognizes factor 
Xa (fXa). This mechanism is called the conformational activation mechanism. Thrombin 
inhibition, in addition to conformational activation, requires the bridging of thrombin and  
antithrombin on a full-length heparin chain. An exosite (shown as‘+ + +’) in thrombin binds non-
specifically to some negative charges available at the extended heparin chain. This mechanism 
is called the bridging mechanism of activation and is the dominant contributor to inactivation 
of thrombin.[ from Medicinal Research Reviews, 2004,. 24, 151-181] 
 
Unfractionated heparin and warfarin are characterized by a narrow therapeutic 
window and by an almost unpredictable dose response profile. Furthermore, 
unfractionated heparin can trigger heparin-induced thrombocytopenia and is unable to 
promote inhibition of fibrin-bounded thrombin and platelet-bounded factor Xa. Low 
molecular-weight heparins feature have a more predictable dose-response relation 
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compared with the unfractionated forms and are avoided of the former limitation, but 
not of the latter.77 
Another class of antithrombotic drugs is represented by direct inhibitors. Among these 
only hirudin and bivalirudin are able to interact with the exosite I. The mechanism of 
action for these agents consists in the inhibition of thrombin bound-fibrin, as well as 
fluid-phase thrombin. However, the current direct thrombin inhibitors do not have a 
superior therapeutic efficacy and safety compared with low-molecular-weight or even 
unfractionated heparins. 
Despite its phenomenal success, current anticoagulation therapy still suffers from the 
risk toward serious bleeding. A direct correlation exists between the intensity of 
anticoagulation and severity of bleeding. Furthermore, each anticoagulant is 
associated with additional problems specific to its class. The need for safer and more 
effective antithrombotic agents clearly exists. 78  
The observation that allosteric "long-range communication" can affect thrombin-fibrin 
interaction provides a novel way through which thrombin activity can be modulated.  
Recent experimental evidences reported by Weitz and coll. and previously described in 
paragraph 3.1.3. seem to indicate the existence of allosteric "long-range 
communication" produced by different ligands, and in particular, by two aptamers, 
HD1 and HD22. An aptamer is a folded single-stranded oligonucleotide that binds to a 
molecular target such as a protein. The advantages of aptamers are manifold, the most 
prevalent being their chemical synthetic access. 79 This renders aptamers distinct from 
antibodies, the second class of macromolecular therapeutics. They cannot, at least 
regarding the current state-of-the-art, be synthesized chemically but their access in 
large scale can be facilitated by fermentation, like other recombinant protein 
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therapeutics. Chemical synthetic access to aptamers is: affordable, highly controlled, 
and allows modifications at a site-specific, hence, in a strategic manner.79 
The first aptamer that was described to bind to and inhibit a coagulation factor is the 
thrombin aptamer HD1. This 15-base DNA oligonucleotide named TBA,80 identified in 
1992, inhibits the procoagulant functions of thrombin such as conversion of fibrinogen 
to fibrin and platelet aggregation. HD1 interacts with one of the two anion-binding 
sites of thrombin, in particular with exosite I (see chapter II). 
HD22 (5'AGTCCGTGGTAGGGCAGGTTGGGGTGACT-'3), is a single-stranded DNA 
consisting of 26 residues. Several evidences suggest that this aptamer folds into a 
quadruplex - duplex mixed structure (Figure 10b) through which recognizes and binds 
specifically the thrombin exosite II.81 
Recently a bivalent aptamer that simultaneously binds to both exosites of thrombin 
was synthesized. The corresponding molecule named HD 1-22 joins the distinct 
thrombin aptamers HD1 and HD22 via a polynucleotidic linkage (Figure 10c). This 
molecule is the most potent “aptameric” thrombin inhibitor to date. 82,83Therefore it is 
clear, that the aptamers may be a good starting point for the search of allosteric 
inhibitors of thrombin. Indeed, an ideal thrombin inhibitor should bind the exosite I, 
competing against pro-coagulants stimuli, but at the same time, it should have the 
ability to induce conformational perturbations to exosite II, increasing the affinity for 
those species that induce anti-coagulants stimuli.  
In other words, if the binding of an inhibitor is also able to induce conformational 
changes to the thrombin, the allostery may act in a synergistic way to create a more 
efficient modulation of the clotting process. Inhibitors having these properties are very 
useful in drug therapy as well as in biotechnological applications.  
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Figure 10. Aptamers that bind to and inhibit thrombin via recognition of exosite I (a), exosite II 
(b), or both exosites (c). [from Hämostaseologie 2011, 4, 258-263] 
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2. Thrombin Binding Aptamer (TBA) 
The first reported consensus sequence able to inhibit thrombin activity was the 15-mer 
oligonucleotide (ON) GGTTGGTGTGGTTGG, usually known with the acronym TBA 
(thrombin-binding aptamer).80 In the presence of thrombin and/or monovalent cations 
TBA folds into a specific three-dimensional structure that dictates its thrombin-binding 
affinity. The structures of TBA alone and in complex with thrombin were determined 
by NMR84-86 and X-ray87-89 methods, respectively. In all experimentally determined 
structures TBA adopted a monomolecular chair-like G-quadruplex folding topology, 
consisting of two G-tetrads connected by one TGT loop and two TT loops. First,87,88 
different TBA−thrombin X-ray complexes were reported, in which TBA adopted either 
the same folding as derived by NMR (PDB ID 1HAO; Figure 11A) or a different one (PDB 
IDs 1HUT and 1HAP; Figure 11B),presenting a diverse positioning of the connecting 
loops. 
 
Figure 11. Schematic drawings of the X-ray derived G-quadruplex structures of TBA as reported 
in PDB IDs 1HAO (A) and 1HUT and 1HAP (B). In (A) TT loops span narrow grooves and TGT 
spans wide grooves, vice versa in (B). White and gray squares indicate G bases in anti and syn 
conformation, respectively. 
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In these X-ray complexes, the aptamer interacts with distinct regions of two thrombin 
molecules, (i) the fibrinogen exosite (namely anion-binding exosite I, ABE I) and (ii) the 
heparin exosite (namely, ABE II) near the carboxylate terminal helix of a neighboring 
thrombin. Thus, according to the adopted folding and the relative orientation with 
respect to thrombin, TBA bound to ABE I by using the TT loops (PDB ID 1HAO; Figure 
11A) or the TGT loop (PDB IDs 1HUT and 1HAP;Figure 11B). A subsequent re-
evaluation90 of the diffraction data of TBA−thrombin complexes87,88 evidenced that the 
NMR derived folding (Figure 11A) could fit all diffraction data if alternative aptamer 
orientations with respect to thrombin were considered. Indeed, according to the 
electron density maps, it was assumed that the oligonucleotide quartet region 
(including the DNA backbone) was correct as reported in the crystal structures, 
whereas, due to the D2 symmetry of the aptamer core, there are four distinct possible 
orientations of the NMR folding that overlap with the core of the X-ray model (Figure 
12). The re-evaluation of the X-ray complex gave similar results among orientations 
I−IV, but orientation III showed the best agreement with the experimental data.90 
Accordingly, different TBA−thrombin complexes in which the aptamer can bind ABE I 
through the TGT loop and ABE II through the TT loops (Figure 12, orientations I and II), 
or the other way around (Figure 12, orientations III and IV), are possible. Supporting 
this view, the newly released X-ray structures of thrombin−TBA−Na+ and 
thrombin−TBA−K+complexes (PDB IDs 4DIH and 4DII, respectively)89showed the 
aptamer interacting with the enzyme assuming orientation IV (Figure 12). Moreover, 
the X-ray structure of human thrombin in complex with a modified TBA containing a 5′-
5′inversion of the polarity site( 3 ′GGT5 ′-5′TGGTGTGGTTGG3′, namely mTBA) has also 
been reported (PDB ID 3QLP).91  
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Figure 12. Representation of the four orientations of the NMR derived folding with respect to 
thrombin corresponding to the D2 symmetry of the quadruplex core assuming the same strand 
polarity of the X-ray complex. 
 
The X-ray complex revealed that the interaction occurs between the TT loops and ABE I 
(orientation III in Figure 12), whereas the TGT loop, particularly T7, is not involved in 
any relevant interaction with the protein. Despite the fact that mTBA binds to 
thrombin with higher affinity with respect to TBA92 it showed poor anticoagulant 
activity if compared to TBA in PT assay.93 On the other hand, Toggle-25t, an RNA 
aptamer that contains 2′-fluoropyrimidine nucleotides, and a 29-mer single-stranded 
DNA, designated DNA60-18 or HD22, bind selectively thrombin at ABE II and they also 
showed limited effect on clotting times.94,95 Because of their thrombin allostery, ABE I 
and ABE II aptamers were used in combination to test their mixed effect on thrombin 
activity.83,96,97 The obtained results showed that synergistic anticoagulant effects can 
be achieved by mixing TBA with Toggle-25t or HD22 and by linking TBA to HD22with an 
appropriate-sized spacer. 
The phase I clinical trial for TBA demonstrated its positive pharmacokinetic profile in 
humans; however, clinical trials were halted after phase I due to suboptimal dosing 
profiles98. To optimize its anticoagulant properties, of particular interest is the 
enlargement of data gathering about TBA structure−activity relationships (SARs) 
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through the development of new derivatives. In the nucleic acids research area the 
introduction of suitable modifications on natural oligonucleotide sequences represents 
a method widely employed to explore the relevance of single nucleotides both on 
secondary structure folding topology and on binding with target proteins. The explored 
modifications involve the nucleobases,99,100 the sugar−phosphate backbone,101,102 and 
the conjugation to flexible non-nucleotide linkers.103-105 
 
2.1. Modified TBA 
Considering the extremely short in vivo half-life (~2 min) of unmodified TBA, a number 
of different approaches have been adopted to improve the enzymatic degradation 
resistance of the aptamer as well as its anti-thrombin effect for potential in vivo 
applications. 
In various strategies TBA maintained its natural backbone and was only modified in the 
sequence: by substituting several bases in the loops103,106,107 and/or in the G-quartets 
or by inserting 5′- or 3′-extensions108,109. Sugimoto et al. for example synthesized TBA 
analogs in which thymine residues were substituted by adenine. This study 
demonstrated that thrombin stabilizes the G-quadruplex via the interaction with 
residues in the loops but not via direct stabilization of G-quartets. 
Some researchers have explored non-natural modifications of the nucleobases99,110-114 
which included: guanines modified with hydrophobic substituents in the N2 and C8 
positions; 6-thio-, 8-amino-,iso-, and 8-bromo-guanine modifications; and thymine 
with 4-thio-uracil substitutions. 
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Figure 13. Structure of (a) G-quadruplex of thrombin binding aptamer and (b) 8-
bromodeoxyguanosine. Modification sites, G1 and G10, are indicated in red. 
 
Other research groups modified the nucleotide backbone of TBA by introducing 
valuable surrogates replacing the natural phosphodiester linkages, such as: neutral 
formacetal groups,101 phosphorothioate linkages,102,115 3′-3′ or 5′-5′ phosphodiester 
bonds91-93and methylphosphonate102 bonds or the nucleoside moieties, with insertion 
within the backbone of: 2′-deoxy-2′-fluoro-D-arabinonucleotides (2′F-araN) 116 (Figure 
14), locked-nucleic acids,117,118 unlocked nucleic acids (UNA),119-121 acyclic thymine 
nucleoside residues.122  
Most of these chemical modifications do not result into relevant improvements in the 
anticoagulant properties of TBA, even if in some reports an increase of the overall 
stability of the G-quadruplex structure and/or of the affinity for thrombin is registered. 
In this scenario, due to the symmetry of TBA and the complexity of the regulatory 
mechanism of thrombin, which includes a long-range allosteric linkage between ABE I 
and ABEII, the exact binding mode of aptamers to thrombin and its correlation with 
the observed biological activity is still a matter of debate. 
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Figure 14. Glycosic conformation equilibrium of dG and 20F-araG with south furanose sugar 
ring. 
 
Herein will describe the results obtained by synthesis and biological characterization of 
several TBA analogs libraries to clarify the key parts of the sequence for the interaction 
with the natural substrate, in order to obtain the best analog more stable and active 
than TBA. 
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3.Investigating the Role of T7 and T12 Residues on the 
Biological Properties of Thrombin-Binding Aptamer: 
Enhancement of Anticoagulant Activity by a Single Nucleobase 
Modification. 
In the understanding of the bases of TBA−thrombin recognition, it was previously 
developed new single-stranded TBA analogues, in which the acyclic nucleoside a 
(Figure 15) replaced, one at a time, all thymine residues along the aptamer 
sequence.122 
 
Figure 15. Acyclic nucleosides mimicking T. The presence of the carbon atom marked with an 
asterisk causes the formation of two diastereomeric ONs when the nucleoside is inserted in the 
TBA sequence. 
 
The modification at position 7 in the T7G8T9 loop (herein TBA-T7a) gives rise to an ON 
that folds into a quadruplex structure that is more stable and active than the 
quadruplex structure formed by TBA. On the other hand, within the four ONs 
containing the acyclic nucleoside a at one position of TT loops, the ON modified at T12 
(herein TBA-T12a) showed the most significant biological properties.122 In line with 
data reported from other authors,121 the results evidenced that modification at T7 and 
T12 along the TBA sequence can be fruitful to improve the biological activity. 
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To investigate the role of the modification at T7 and T12 in affecting the structural 
stability and the biological activity, I synthesized two new modified TBAs, named TBA-
T7b andTBA-T12b, which differed from the previously reported analogues only in the 
thymidine base coupled with the acyclic linker, which was bulked by fusing a 
hydrophobic five member cycle with the pyrimidine ring (b, Figure 15). The abilities of 
TBA-T7b and TBA-T12b to fold into G-quadruplex structures, as well as their biological 
properties, were evaluated by CD and 1H NMR experiments and by PT and purified 
fibrinogen clotting assays, respectively. Finally, a computational study allowed the 
analysis of the obtained SARs. 
 
3.1 RESULTS AND DISCUSSION 
Synthesis of Monomer 6. The synthesis of the modified acyclic nucleoside 
phosphoramidite building block 6, used for the automated synthesis of TBA-T7b and 
TBA-T12b, is summarized in Scheme 1. 
The synthesis of N1-alkylated intermediate 3 was performed via Mitsunobu reaction123 
between 2, obtained as described under Experimental Section, and 1. The yields of this 
coupling reaction were strongly dependent on the initial temperature of the system 
and on the order in which the reagents were added. We found that temperatures 
lower than 30 °C were always detrimental to the reaction yield, and that higher yields 
(45−50%) were obtained by mild heating (30 °C) of a dioxane solution containing 2 and 
triphenylphosphine followed by addition of di-tert-butylazodicarboxylate and finally a 
dioxane solution of protected linker 1 (100 μL of solvent per 1 mmol). 
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Scheme 1. Synthesis of Monomer 6. (i) 1 0.94 g (5.9 mmol), 2 1.50 g (5.9 mmol), 
triphenylphosphine 2.28 g (8.7 mmol), di-tert-butylazodicarboxylate 2.1 g (9.1 mmol), dry 
dioxane (70 mL), 24 h, 30°C, yields 43%; (ii) (a) 3 1.0 g (2.5 mmol), Dowex H+ 450 mg, 
MeOH/H2O (9:1 v/v) 100 mL; (b) aqueous NaOH (1.0 M, 5 mL) yields 98%; (iii) 4 640 mg (2.5 
mmol), 4,4′-dimethoxytrytylchloride 541 mg (1.6 mmol), 2,4-dimethylaminopyridine 15 mg 
(0.12 mmol), pyridine (20 mL), acetonitrile (10 mL), 1.5h, rt, yields 45%; (iv) 5 600 mg (1.1 
mmol), 2-cyanoethyldiisopropylchlorophosphoramidite 300 μL (1.2 mmol), DIPEA 600 μL (3.6 
mmol), DCM (8 mL), 40 min, rt, yields 99%. 
 
The intermediate 4 was obtained by removing both the linkerand nucleobase 
protecting groups from 3 using a one-pot procedure (see Experimental Section). 
Finally, 4 was functionalized to phosphoramidite building-block 6 using standard 
procedure. 
The acyclic nucleoside 6 was inserted as a T mimic at position 7 or 12 along the TBA 
sequence to obtain TBA-T7band TBA-T12b, respectively. 
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Structural Characterization TBA-T7b and TBA-T12b were characterized by circular 
dichroism (CD), CD melting, and 1H NMR for their ability to fold into G-quadruplexes. 
Circular dichroism is a useful technique to preliminarily study a G-quadruplex structure 
or to confirm a particular conformation inferred by other more informative 
techniques. The introduction of the new acyclic nucleoside b at position 7 or 12 does 
not affect the overall G-quadruplex topology formed in solution. CD profiles of TBA-
T7b and TBA-T12b are similar to those of TBA in both PBS and K+ buffer (left and right 
panels, respectively, in Figure 16), showing maxima at about 208, 245,and 295 nm and 
a minimum at 267 nm. As expected, positive CD bands have higher molar ellipticities in 
K+ buffer than in PBS, according to the well-known dependence of G-quadruplex 
stabilities from the type of cations present in the buffer solution.124-126 
 
 
Figure 16.CD profiles in PBS (left) and in potassium phosphate buffer (right); [ON]=2.0 × 10−5 M. 
 
The 1H NMR analysis, performed at temperatures in the range of 25−50 °C, confirmed 
that TBA-T7b and TBA-T12b form a stable G-quadruplex structure when annealed in 
K+buffer. However, 1H NMR spectra appear more crowded than expected for a single 
quadruplex species, even at 25 °C (Figure 17), where only 14 aromatic signals and 8 
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imino proton signals are expected. This finding was previously explained by 
considering that the replacement of a T residue with the acyclic nucleoside a produces 
two closely related diastereomeric G-quadruplex forming ONs.122 
 
 
Figure 17. 1H NMR spectra of TBA-T7b and TBA-T12b recorded at 25 °C in K+ buffer. 
 
Although both modified ONs show Tm values higher than that of TBA (Figure 18 and 
Table 1), the replacement of T7 with the acyclic nucleoside b stabilizes the resulting G-
quadruplexes more efficiently than replacement of T12. 
In fact TBA-T7b and TBA-T7a show the same melting profile, with a Tm higher than 
that of TBA (Table 1), it can be concluded that the sole presence of the acyclic linker 
unit at position 7 is responsible for the structural stabilizing effect.  
These data account for the nucleobase 7 always positioned outside the G-quadruplex 
core and not involved in intramolecular interactions, as well as for the reported 
stabilizing role played by T4 and T13 on TBA structural stability.  
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Figure 18. CD melting curves of TBA and its analogues in potassium phosphate(continuous 
lines) or PBS (dotted lines) buffer. Concentration of each ON was 2.0 × 10−5 M. The curves were 
obtained by monitoring the variation of absorbance at 295 nm from 10 to 80 °C at 0.5 °C/min. 
 
 
aData taken from ref.122 
Table 1. Tm Values of TBA and Its Analogues 
 
In line with these results, a similar increase in Tm value has also been observed by 
replacing the sugar moiety of T7 with a different acyclic linker.121 
 
PT Assay. The anticoagulant activity in the presence of all thrombin substrates and 
cofactors was evaluated by PT assay.PT analyses were performed at [ON] of 2 and 20 
μM after 2min of incubation with human plasma (Figure 19). 
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Figure 19. Concentration-dependent response, following 2 min ON incubation with human 
plasma at 2 (A) or 20 μM (B) [ON]. PT values are expressed in seconds. Each measurement was 
performed in triplicate and is shown as the mean ± SEM. The basal PT time is 13.4 ± 0.2 s. 
 
To better understand the effects induced by the presence of nucleoside b on the 
anticoagulant activity, we compared the prolonging of clotting time caused by TBA-T7b 
and TBA-T12b with that of TBA and those of the previously reported122analogues TBA-
T7a and TBA-T12a (Table 2). It is noteworthy that TBA-T7b prolonged the basal PT 
valueto a significantly larger extent with respect to TBA and TBAT7a (Figure 19). 
Replacement of nucleoside a for b was more effective also at position 12 (Table 2).  
 
aPT values are expressed in seconds.  bData taken from ref.122 
 
Table 2. PT Values Measured after 2 min of incubation using 20 μM ON concentration and Fold 
Increases of Basal PT Time (13.4 ± 0.2 s). 
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In particular,TBA-T12b is less active than TBA at 2 μM, but showed a greater increase 
of activity at higher concentration, thus attaining that of TBA at 20 μM (Figure 19). 
To exclude that the observed activity of modified aptamers could be due to higher 
nuclease stability with respect to TBA, the experiments were repeated, changing the 
incubation time of TBA and analogues with plasma from 30 s to 15 min. PT results 
were almost unchanged for all sequences (Table 3). 
 
Table 3. Prolonged fibrinogen clotting time results in presence of human thrombin. Each value 
was calculated subtracting the clotting time produced by thrombin alone from that measured 
in the presence of one of the aptamers. The measurements were performed preincubating for 1 
min 200 μL of purified fibrinogen solution (2.0 mg/mL in PBS) with various concentrations of 
aptamers. The reaction started by the addition of 100 μL of human thrombin solution (10 NIH 
per mL) and clotting time was recorded. In absence of any inhibitor, the measured clotting time 
for human thrombin was 24.9± 0.5 s. 
 
Fibrinogen Assay Using Human and Bovine Thrombin. The new ONs were subjected to 
purified fibrinogen clotting assay to evaluate their ability to inhibit the conversion of 
soluble fibrinogen into insoluble strands of fibrin in the absence of any other thrombin 
ligands/effectors (Figure 20). 
The assay was performed using various concentrations of each aptamer. The purified 
fibrinogen solution was preincubated with the aptamer and the reactions were 
initiated by the addition of human thrombin and clotting times were recorded. 
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The fibrinogen assay results evidenced that at all ON concentrations tested, the most 
efficient inhibitor is the unmodified TBA sequence (Figure 20A), thus reversing the 
results gathered from the PT assay. 
 
 
Figure 20. Effects of aptamers on human (A) and bovine (B) thrombin clotting time in 
fibrinogen solution. The results are expressed as the ratio ofclotting times measured in the 
absence and in the presence of the aptamers. The effects are reported as a function of log 
[ON]. Each measurementwas performed in triplicate and is shown as the mean ± SD. 
 
To further investigate this phenomenon, the fibrinogen assay was performed by using 
bovine thrombin, which differs from human thrombin in some residues of the 
fibrinogen-binding site (ABE I) that are crucial for TBA−thrombin interaction (see next 
paragraphs for details). By changing the source of the target enzyme, both modified 
sequences showed a substantial increase in their ability to inhibit thrombin activity 
(Figure 20B), whereas the inhibitory activity of TBA was only slightly increased; as a 
consequence, TBA-T7b became again the best inhibitor. 
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Conformational Search on TBA and Modified Analogues TBA-T7b and TBA-T12b. 
An extensive molecular modeling study, including molecular mechanics (MM) and 
dynamics (MD) calculations, was undertaken to analyze the SARs of new modified 
TBAs. In particular, to investigate the conformational properties of TBA and the new 
modified aptamers, a simulated annealing(SA) procedure followed by MM energy 
minimization was applied. Following the criteria described under Experimental Section, 
resulting conformers were analyzed and each nucleotide of loops was classified on the 
basis of (i) χ torsional angle values, to identify the conformation of the glycosidic bond 
(i.e., syn, anti, or s/a); and (ii) the interatomic distance between its own centroid and 
that of the two G-tetrads, to investigate the position of loop nucleotides with respect 
to the guanine planes (i.e., “stacked” or “not-stacked”). Occurrence rates were 
calculated and compared to those obtained for TBA. Because the replacement of T7 
and T12 residues with nucleoside b produced a mixture of diastereoisomers, 
characterized by S or R configuration at the acyclic linker, the occurrence rates 
reported in Tables 4 and 5 are the mean of the values obtained for the two 
diastereoisomers. 
 
 
 
Table 4. Calculated Occurrence Rates (Percent) of syn, anti, and s/a Conformers of TGT and TT 
Glycosidic Bonds. 
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The structural analysis evidenced that, although inducing some variations, the 
introduced modifications at T7 and T12 did not cause a reversal of the conformational 
preference of the glycosidic bonds with respect to TBA (Table 4). Consequently, in 
agreement with previously reported NMR studies,86 TBA and modified aptamers TBA-
T7b and TBA-T12b conserved an overall preference for the anti conformation of 
thymines in TGT and TT loops. With regard to the stacking of the TGT loop nucleobases 
on the G-tetrads, TBA-T7b and TBA-T12b present an increased stacking of T9 and a 
decreased stacking of G8 (Table 5). Nevertheless, the conformational features of the 
TGT loop still evidenced the same trend of TBA with the following order of residue 
stacking on the G-tetrads: G8 > T9 > T7. 
The two modified analogues showed a similar conformational behavior at the T3 T4 
loop because, either in TBA-T7b or in TBA-T12b, the rate of stacked conformation of T3 
and T4 decreased and increased, respectively, with respect to TBA, evidencing a 
conformational linkage between TGT and T3T4loops. On the contrary, different results 
were obtained for theT12T13 loop. In fact, as expected, the substitution of T12 with 
the acyclic nucleoside b (TBA-T12b) affected the conformational flexibility of the T12 
T13 loop, inducing a decreased stacking rate of both nucleobases, which was not 
observed in TBA-T7b (Table 5).  
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Table 5. Calculated Occurrence Rates (Percent) of Conformers Presenting TGT and TT 
Nucleobases “Stacked”on the Guanine Planes. 
 
NMR studies performed on TBA84 revealed that the positioning of T4 and T13 plays a 
key role in quadruplex folding and stability; accordingly, due to the increased stacking 
of T4 and T13 on the guanine planes, TBA-T7b was structurally more stable than TBA in 
CD melting experiments (Table 1 and Figure 18). 
 
Molecular Modeling Studies on Aptamer Interaction with Human and Bovine 
Thrombin. With the aim of identifying the effects of the new structural modifications 
on aptamer−thrombin interactions, first, all possible aptamer−thrombin binding modes 
and the corresponding binding interactions were analyzed (PDB IDs 1HAO, 1HAP, 
1HUT,4DIH, and 4DII; see Experimental Section). This study revealed that the various 
binding orientations of TBA with respect to human thrombin (Figures 11 and 12) 
produced different binding modes in the crystal complexes sharing similar interactions 
with ABE I but involving different aptamer residues (Figure 21). 
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Figure 21. Cartoon (left) and 3D (right) structure of the different binding orientations of TBA 
with respect to human thrombin ABE I(green). (A, C, and E) Amino acid residues involved in 
TBA−thrombin interactions are evidenced in black; where mutated, the corresponding bovine 
residues are reported in red. The blue curve and straight arrows indicate loop nucleotides 
“stacked” or “not-stacked” on G-tetrad, respectively. (B) PDB ID 1HAO (TBA carbons = cyan); 
(D)PDB ID 4DIH (TBA carbons = yellow); (F) PDB ID 1HAP (TBA carbons = magenta). Protein 
carbons are colored in green, residues within TBA binding site that are mutated in bovine 
thrombin are shown and labeled. The nucleotides T3, T7, and T12 are evidenced as ball and 
stick. Heteroatoms are colored as follows: O = red; N = blue; P = magenta. Hydrogens are 
omitted for the sake of clarity. 
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Indeed, a thymine residue of TBA always interacts with ABEI hydrophobic cleft lined by 
Ile24, His71, Ile79 and Tyr117, but, depending on the binding mode, the interactions 
involveT3 (Figure 21C,D), or T7 (Figure 21A,B), or T12 (Figure 21E,F). 
T7 interacts penetrating into the hydrophobic cleft more thanT12 and T3 (Figure 21F vs 
Figure 21B,D); while the positioning ofthese latter resulted identical due to the 
symmetry of the twoTT loops (Figure 21B vs Figure 21D). By consequence, a second 
ABE I subsite, including Gln38, Tyr76 and Ile82, interacts withT12 or T3, depending on 
the binding orientation (Figure 21A−D). When the TGT loop binds to ABE I, the 
interaction with this second subsite is absent (Figure 21,F). 
Second, to identify the structural differences in TBA-binding site, experimentally 
determined structures of human and bovine thrombin were compared (PDB IDs are 
listed in the Experimental Section). Only three TBA-binding site residues,Ile24, Asn78, 
and Ile79, were mutated in bovine thrombin, with no significant variation of the 
backbone structure (Figure 21). Human thrombin Asn78 residue (replaced by a lysine 
in bovine thrombin) interacts only with the TGT loop, establishing an H bond 
interaction with the phosphate group of T9 (PDB IDs1HUT and 1HAP; Figure 21E,F). 
On the contrary, the interactions with human ABE I hydrophobic cleft containing Ile24 
and Ile79 are conserved in all crystal complexes and involve T3 or T7 orT12 depending 
on TBA-binding orientation (Figure 12). The replacement of these two isoleucine 
residues in human thrombin by two valine residues in the bovine homologue 
determines an enlargement of the employable volume within the ABE I cleft. We then 
calculated the occurrence rates of TBA, TBA-T7b,and TBA-T12b SA/MM conformers 
presenting solvent accessible surface areas of residues 3, 7, and 12 equal to or greater 
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than that of the corresponding residue of TBA binding the ABE I hydrophobic cleft in 
experimentally determined complexes (Table 6). 
 
 
Table 6. Occurrence Rates (Percent) of TBA, TBA-T7b, andTBA-T12b SA/MM Conformers 
Presenting a Solvent-Accessible Surface Area (Å2) of Residues 3, 7, and 12 Equal to or Greater 
than That of the Corresponding Residue ofTBA Assuming the Bioactive Conformation at the ABE 
I Hydrophobic Cleft. 
 
Interestingly, the replacement of T7 and T12 with the acyclic nucleoside b determined 
in both cases a greater rate of conformations presenting a solvent-exposed 
conformation. Moreover, in agreement with the results reported in Tables 4 and 5, T3 
is more exposed to the solvent in the new modified aptamers than in TBA. Finally, we 
calculated the occurrence rates of bioactive conformations of residues at positions 3, 
7, and 12 resulting from SA/MM calculations on TBA, TBA-T7b, and TBA-T12b (Figure 
22 and Table 7). 
With this aim, all obtained conformers were superimposed on the experimentally 
determined TBA−thrombin complexes by fitting the guanine tetrads to evaluate the 
overlap with the residue interacting with the ABE I hydrophobic cleft (see Experimental 
Section for details). Obtained results show that TBA-T7b presents an increased rate of 
bioactive conformations if compared to TBA; on the contrary, the substitution of T12 
with b decreases the rate of bioactive conformations of T3 and T7. Interestingly, the 
replacement of T7 and T12 with the acyclic nucleoside b determined in both cases a 
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greater rate of conformations presenting a solvent-exposed position able to drive the 
interaction with the ABE I hydrophobic cleft. Nevertheless, likely due to the higher 
flexibility of the TGT loop with respect to the TT loops, there is a higher occurrence 
rate of T7b assuming the ABE I bioactive conformation compared to T3 and T12b 
(Table 7 and Figure 22). In the new TBA derivatives TBA-T7b and TBA-T12b, the 
introduction of the acyclic linker facilitates the extension of the phosphate backbone 
toward the solvent and the penetration of the modified nucleobase within the ABE I 
hydrophobic cleft, thus amplifying the steric hindrance caused by the presence of the 
five member cycle on modified nucleobase b (Table 6 and Figure 22). 
Accordingly, the presence of the smaller Val24 andVal79 residues in bovine thrombin 
could explain the increased activity of the new modified TBA analogues for this 
enzyme. The observed higher activity of TBA-T7b is indeed correlated to the calculated 
higher rate of bioactive conformations at the ABE I hydrophobic cleft with respect to 
TBA and TBA-T12b (Table 7 and Figure 22). This hypothesis is supported by the 
previously reported activity of TBA-T7a and TBA-T12a,122which, lacking the steric bulk 
at the modified nucleoside, was more active in the fibrinogen assay using human 
thrombin. On the other hand, the charged group at the lysine side chain allows the 
establishment of an ionic interaction with the modified TGT phosphate backbone of 
TBA-T7b, likely contributing to the enhancement of inhibitory ability. 
On these bases, the apparent incongruence of PT and fibrinogen assay results, using 
human thrombin, can be interpreted by taking into account the effects of different 
aptamer binding modes on thrombin allostery. In the PT assay a number of thrombin 
ligands/effectors other than fibrinogen that are able to modulate thrombin activity are 
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present,1,2,41,68,127-129thus driving different binding modes; the new modified aptamers 
could differently affect this ligand/effector binding network. 
In this scenario, it is noteworthy that the 65−84 thrombin loop, involved in specific 
interactions with the modified nucleobase of the new TBA derivatives according to our 
binding mode hypothesis, has been proved to be responsible for the allosteric long-
range communication among ABE I, the catalytic site, and ABE II.68 Altogether, our 
results reveal the absence of a direct correlation between the structural stability and 
the anticoagulant property in our series of modified TBAs, suggesting that the role 
played by T7 (placed in the TGT loop) and T12(placed in the TT loop close to the 3′ 
terminus) in the biological activity of TBA and its analogues could involve alternative 
aptamer binding modes and the complex and not yet fully understood allosteric 
mechanism of action of thrombin. 
 
 
 
 
Table 7. Occurrence Rates (Percent) of Bioactive Conformations at the ABE I Hydrophobic Cleft 
of Residuesat Positions 3, 7, and 12 Resulting from SA/MMCalculations 
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Figure 22. TBA (green; A−C), TBA-T7b (orange; D−F), and TBA-T12b (white; G−I) SA/MM 
conformers presenting residue 3, 7, or 12 assuming ABE I hydrophobic cleft binding 
conformation. Molecular models are superimposed on 4DIH (A, D, G; yellow), 1HAP (B, E, H; 
pink), or 1HAO(C, F, I; cyan) by fitting the guanine tetrads. All conformers of TBA and the mean 
of those obtained for the two diastereoisomers of TBA-T7b andTBA-T12b are shown. For the 
sake of clarity only the residue interacting with the ABE I hydrophobic cleft is displayed and 
hydrogens are omitted. Heteroatoms are colored as follows: O = red; N = blue; P = magenta. 
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3.3 CONCLUSIONS 
Bringing together the so far acquired knowledge of the thrombin−TBA interaction and 
thrombin allosteric regulatory mechanism with reported SAR data, I determined that 
the G quadruplexes formed by the modified TBAs can bind the thrombin ABE I 
hydrophobic cleft by using either TGT or one of the two TT loops. Reported results 
indicate that the incoherency of their behaviors in the two explored biological tests is 
due to the molecular process through which they exert the anticoagulant activity, 
which is surely more intricate than a competitive inhibition with the fibrinogen-binding 
site. Besides their high anticoagulant activity, these molecules represent valuable tools 
to further explore the complex regulatory mechanism of thrombin during plasma 
coagulation that is, as yet, not completely clarified. 
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3.4 EXPERIMENTAL SECTION  
General Procedure. Chemicals and anhydrous solvents were purchased from Fluka-
Sigma-Aldrich. TLCs were run on Merck silica gel 60 F254 plates. Silica gel 
chromatography was performed by using Merck silica gel 60 (0.063−0.200 mm). An API 
2000 (Applied Biosystem) mass spectrometer was used to perform the analyses of the 
intermediates and monomer 6. NMR experiments were recorded using Varian Mercury 
Plus 400 MHz and Varian UNITYINOVA 500 and 700MHz spectrometers and processed 
using the Varian VNMR software package. Reagents and phosphoramidites for DNA 
synthesis were purchased from Glenn Research. ON syntheses were performed on a 
PerSeptive Biosystem Expedite DNA synthesizer. HPLC purifications and analyses were 
carried out using a JASCO PU-2089 Plus HPLC pump equipped with a JASCO BS-997-01 
UV detector. The purity of the final products was determined as >95% by using a C-18 
RP analytical column (C-18 Purospher STAR, Merck) eluted by a gradient of CH3OH in 
H2O (from 0 to 100% in 30 min). CD experiments were performed on a JASCO 715 
spectropolarimeter equipped with a PTC-348 temperature controller. 
Synthesis of Monomer 6. (a) 3-Benzoyl-6,7-dihydro-1Hcyclopenta[d]pyrimidine-
2,4(3H,5H)-dione (2). Nucleobase 6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-
dione was obtained as previously reported by Renault et al.130 and converted in its N3 
benzoyl derivative 2.122 
1H NMR (400 MHz; mixture of CD3OD and CDCl3),δ 7.75 (d, J = 8.0 Hz, 2H), 7.60 (t, J = 
8.0 Hz, 1H), 7.43 (t, J = 8.0 Hz,2H), 3.03 (t, J = 7.3 Hz, 2H), 2.67 (t, J = 7.3 Hz, 2H), 2.10 
(q, J = 7.3Hz, 2H);  
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13C NMR (100 MHz; mixture of CD3OD and CDCl3), δ169.3, 166.3, 155.2, 147.3, 134.2, 
132.2, 128.9, 128.3, 127.5, 127.0,113.4, 34.8, 30.5, 18.0. 
ESI mass (positive mode), calculated 256.1;found 257.1 [M + H]+, 279.1 [M + Na]+. 
 
(b)3-Benzoyl-1-[(2,2,5-trimethyl-1,3-dioxan-5-yl)methyl]-6,7-dihydro-1H-
cyclopenta[d]pyrimidine-2,4(3H,5H)-dione (3).  
Compound 2 (1.5 g, 5.9 mmol) was suspended in 70 mL of dry dioxane at 30° C in the 
presence of triphenylphosphine (2.28 g, 8.7 mmol) before the addition of di-tert-butyl 
azodicarboxylate (2.1 g, 9.1 mmol).To the resultant mixture, after 10 min of stirring at 
room temperature, was added 5.9 mmol of 1 dissolved in dry dioxane (300 μL). The 
reaction mixture was stirred at room temperature for 18 h under argon. The solution 
was concentrated under reduced pressure and the residue purified by column 
chromatography on silica gel eluted with 95:5 Et2O/CH2Cl2 to give 3 as a white solid 
(yield 43%, Rf 0.70). 
1H NMR (400 MHz; CDCl3), δ 7.98 (d, J = 8.0 Hz, 2H), 7.60 (t, J = 8.0Hz, 1H), 7.43 (t, J = 
8.0 Hz, 2H), 4.0 (bs, 2H), 3.62 (m, 4H), 3.03 (t, J= 7.3 Hz, 2H), 2.66 (t, J = 7.3 Hz, 2H), 
2.09 (q, J = 7.3 Hz, 2H), 1.38(s, 3H), 1.42 (s, 3H), 0.87 (s, 3H).  
ESI mass (positive mode),calculated 398.2; found 399.2 [M + H]+, 421.2 [M + Na]+. 
 
(c) 1-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropyl)-6,7-dihydro- 
1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione (4). 
Compound 3 (1.0 g, 2.5 mmol) was suspended in 9:1 MeOH/H2O (100 mL)containing 
450 mg of Dowex 50WX8 (H+). After 8 h at room temperature, a NaOH 0.5 M aqueous 
solution was slowly added to neutralization. The solution was filtered and, in turn, 
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basified with NaOH 1.0 M (5 mL) to remove the N-3 benzoyl group from the 
nucleobase. After 12 h at room temperature, the pH of the reaction was neutralized, 
the solvent was evaporated under vacuum, and the residue was dissolved in MeOH 
and purified by HPLC (C-18 reverse phase column, Grace Davison Discovery Sciences, 
eluted with ACN inH2O from 0 to 50% in 30 min) to give 4 as a white solid (yield 98%, 
elution time 15 min).  
1H NMR (700 MHz; CD3OD), δ 3.80 (bs, 2H),3.41 (d, J = 11.4 Hz, 2H), 3.38 (d, J = 11.4 
Hz, 2H), 3.03 (t, J = 7.3Hz, 2H), 2.66 (t, J = 7.3 Hz, 2H), 2.09 (q, J = 7.3 Hz, 2H), 0.87 
(s,3H);  
13C NMR (175 MHz; CD3OD), δ 163.8, 161.4, 155.7, 113.6,66.6, 49.5, 44.0, 34.2, 28.2, 
22.6, 17.8;  
NOESY (700 MHz; CD3OD),fundamental NOE signal between 3.80 and 3.03 ppm that 
confirms the linker at the N1 position.  
ESI mass (positive mode), calculated 254.1;found, 255.3 [M + H]+, 277.3 [M + Na]+, 
293.2 [M + K]+. 
 
(d) 3-(Bis(4-methoxyphenyl)(phenyl)methoxy)-2-((2,4-dioxo-3,4,6,7-tetrahydrohydro-
1H-cyclopenta[d]pyrimidin-1-yl)methyl)-2-methylpropyl-2-
cyanoethylDiisopropylphosphoramidite (6).  
Compound 4 (640 mg, 2.5 mmol), 4,4′-dimethoxytrytyl chloride (541 mg, 1.6 mmol), 
and 4-dimethylaminopyridine (15.0 mg, 0.12 mmol) were dissolved in dry pyridine (20 
mL) and dry ACN (10 mL). The resulting solution was stirred at room temperature 
under argon for 1.5h. Dry methanol (200 μL) was then added to quench the reaction. 
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After 30 min under stirring, the solution was concentrated under reduced pressure and 
the residue purified by column chromatography on silica gel (eluted with 50:50:1 
EtOAc/hexane/Et3N) to give monodimethoxytritylated 5 as a clear yellow solid (44% 
yield from 4;Rf 0.51 in EtOAc/hexane 1:1 v/v). The solid (600 mg, 1.1 mmol) was dried 
in vacuo overnight before being dissolved in anhydrous DCM (8mL) and 
diisopropylethylamine (600 μL, 3.6 mmol) under argon. Three hundred microliters of β-
cyanoethyldiisopropylchlorophosphoramidite was then added (1.2 mmol). After 40 
min, the reaction was quenched by the addition of dry methanol (100 μL), diluted with 
ethyl acetate (15 mL), and finally washed with 10% sodium carbonate solution (15 mL) 
and brine (15 mL). The organic layer was dried on magnesium sulfate and concentrated 
in vacuo. The residue was purified by silica gel chromatography eluted with DCM, ethyl 
acetate, and triethylamine (80:10:10). The fractions containing the product were 
collected and concentrated under vacuum, yielding 6 as a white foam (99% yield; Rf 
0.65 in CHCl3/MeOH/TEA 97:3:0.05 v/v/v).  
1H NMR (700 MHz; CDCl3), δ 7.90 (2H), 7.38 (2H), 7.35 (4H), 7.12(1H), 6.85 (4H), 3.90 
(2H), 3.70 (6H), 3.65 (2H), 3.60 (2H), 3.45(2H), 3.39−3.02 (4H), 2.60−2.45 (4H), 2.16 
(2H), 1.45 (3H), 1.09(6H), 1.04 (6H);  
13C NMR (175 MHz; CDCl3), δ 158.6, 151.6, 147.3,139.4, 135.1, 130.3, 129.1, 127.8, 
127.7, 127.1, 113.1, 64.4, 60.4, 55.2,47.3, 33.6, 29.7, 27.6, 20.9, 19.3, 17.3;  
31P NMR (202 MHz, CDCl3), δ146.1 and 145.9. 
ESI mass (positive mode), calculated 756.3; found757.9 [M + H]+, 779.9 [M + Na]+. 
 
Synthesis of Oligomers. TBA and analogues were synthesized by using standard solid 
phase DNA chemistry on controlled pore glass (CPG) support following the β-
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cyanoethylphosphoramidite method. The oligomers were detached from the support 
and deprotected by treatment with an aqueous ammonia solution (33%) at 55° C 
overnight. The combined filtrates and washings were concentrated under reduced 
pressure, dissolved in H2O, and purified by HPLC using an anionic exchange column 
eluted with a linear gradient (from 0 to 100% B in 30 min) of phosphate buffer at pH 
7.0 (A, 20 mM NaH2PO4 aqueous solution containing 20% CH3CN; B, 1.0 M NaCl, 20 
mM NaH2PO4 aqueous solution containing 20% CH3CN). The oligomers were 
successively desalted by molecular exclusion chromatography on Biogel P-2 fine. The 
purity was checked on HPLC by using reverse phase column. The concentrations of the 
samples used in CD and UV experiments were determined by measuring the 
absorbance at 260 nm at 80 °C and using the open access program available 
onhttp://basic.northwestern.edu/biotools/OligoCalc.html.131 
 
NMR Experiments. 1D NMR spectra were acquired as 16384 data points with a recycle 
delay of 1.0 s at temperatures in the range of 2−50 °C. Data sets were zero filled to 
32768 points prior to Fourier transformation and apodized with a shifted sine bell 
squared window function. The pulsed-field gradient DPFGSE132,133sequence was used 
for H2O suppression. NMR samples of TBA-T7b and TBA-T12b (0.5 mM single-strand 
concentration) were prepared in 100 mM K+ buffer(H2O/D2O 9:1 v/v containing 90 
mM KCl, 10 mM KH2PO4, and 0.2mM EDTA). 
 
CD Experiments. To perform CD experiments, each ON was dissolved in the potassium 
(90 mMKCl, 10 mM KH2PO4, pH 7.0) or PBS (Sigma-Aldrich; 10 mM phosphate buffer, 
2.7 mMKCl, 137 mMNaCl, pH 7.4) phosphate buffer at the final ON concentration of 
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2.0 ×10−5 M and submitted to the annealing procedure (heating at 90°C and slowly 
cooling at room temperature). Before each experiment, the samples were equilibrated 
at 10°C for 30 min. CD spectra were recorded from 200 to 360 at 100 nm/min scanning 
rate, 16 s response, and 1.0 nm bandwidth. Each CD profile was obtained by taking the 
average of three scans from which the spectrum of background buffer was subtracted. 
CD melting curves were obtained by monitoring the variation of absorbance at 295 nm 
from 10 to 80°C. Two melting experiments for each ON were recorded at 0.5°C/min 
heating rate. 
 
Prothrombin (PT) Time. PT time was measured by using a Koagulab MJ Coagulation 
System with a specific kit RecombiPlas TinHemosIL (Instrumentation Laboratories, 
Lexington, MA, USA). The procedure was performed according to the manufacturer’s 
instructions. In our experimental protocol a time course of each ON or vehicle 
incubated with 100 μL of plasma at 37 °C has been performed. For three valuation of 
PT at 20.0 μM, in the apposite microtube, 2.0 μL of the corresponding ON solution (1.0 
× 10−3 M in PBS) or vehicle was added. The PT at final ON concentration of 2.0 μM was 
determined by using 2.0 μL of a diluted ON solution (the initial ON solution 1.0 ×10−3 M 
in PBS was diluted at a final concentration of 1.0 × 10−4 M).Using six different 
incubation times from 30 s to 15 min (i.e., 30 s and 1, 2, 5, 10, and 15 min) 200 μL of 
the kit solution containing Recombiplastin was added with consequent activation of 
extrinsic pathway. The PT measurement, for each incubation time, was produced in 
triplicate, and the average and its standard error values were calculated. The basal 
clotting time was determined by measuring the clotting time in the absence of any ON. 
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The fold increase of basal PT time was calculated as the ratio between the measured 
PT time in the presence of each ON and the basal PT value (13.4 ± 0.2 s). 
 
Purified Fibrinogen Clotting Assay. ONs were incubated for 1min at 37 °C in 200 μL of 
buffer (20 mM tris acetate, 140 mM NaCl,2.7 mM KCl, 1.0 mM MgCl2, 1.0 mM CaCl2, 
pH 7.4) containing 2.0mg/mL of fibrinogen (fibrinogen from human plasma, F 3879, 
Sigma-Aldrich). One hundred microliters of human (Sigma-Aldrich, T8885,human 
thrombin suitable for thrombin time test) or bovine(HemosIL, Thrombin Time Kit, 
Instrumentation Laboratories)thrombin (10 NIH per mL) was then added to the 
solution containing the fibrinogen and the ON. The time required to clot was measured 
using a Koagulab MJ Coagulation System. The clotting time of each ON was determined 
in triplicate at different concentrations. The basal clotting time was determined by 
measuring the clotting time in the absence of any ONs. Prolonged clotting time was 
obtained by subtracting the basal clotting value from each ON clotting time. The ratio 
of basal and prolonged clotting time versus log [ON] was reported. 
 
Molecular Modeling. Molecular modeling calculations were performed on SGI Origin 
200 8XR12000 and E4 Server Twin 2 xDual Xeon 5520, equipped with two nodes. Each 
node was 2 x Intel Xeon QuadCore E5520, 2.26 GHz, 36 GB RAM. The molecular 
modeling graphics were carried out on SGI Octane 2 work stations. 
(a) Conformational Analysis. Experimentally determined structure sof TBA alone (PDB 
ID 148D) and in complex with thrombin(PDB IDs 1HAO, 1HAP, and 1HUT) were 
downloaded from Protein Data Bank (PDB, http://www.rcsb.org/pdb/) and analyzed 
using the Homology module of Insight 2005 (Accelrys Software Inc., San Diego,CA, 
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USA). Hydrogens were added to all of these structures considering a pH value of 7.4 
(Biopolymer Module, Insight 2005).Because the replacement of T7 and T12 residues 
with nucleoside b produced a mixture of diastereoisomers characterized by S or R 
configuration at the acyclic linker, for each new TBA analogue TBAT7band TBA-T12b, 
the two diastereoisomers were built by modifying the experimentally determined 
structure of TBA in complex with thrombin (PDB ID 1HAO; Insight 2005 Builder 
module). Atomic potentials and charges were assigned using the CVFF force field.134 
The conformational space of TBA (PDB ID 1HAO) and the new modified analogues was 
sampled through 200 cycles of simulated annealing (SA) followed by molecular 
mechanics (MM) energy minimization. During the SA procedure, the temperature is 
altered in time increments from an initial temperature to a final temperature by 
adjusting the kinetic energy of the structure (by rescaling the velocities of the atoms). 
The following protocol was applied: the system was heated to 1000 K over 2000 fs 
(time step of 1.0 fs); a temperature of1000 K was applied to the system for 2000 fs 
(time step of 1.0 fs) to surmount torsional barriers; successively, the temperature was 
linearly reduced to 300 K in 1000 fs (time step of 1.0 fs). Resulting conformations were 
then subjected to MM energy minimization within Insight 2005 Discover_3 module 
(CVFF force field) until the maximum rms derivative was <0.001 kcal/Å, using a 
conjugate gradient135 as the minimization algorithm. To reproduce the physiological 
environment where these molecules act and, to evaluate the effects of the implicit 
solvent, we sampled the conformational space through the combined procedure of 
SA/MM calculations, using the dielectric constant of the water (ε = 80r). 
Moreover, to allow a complete relaxation of the structures preserving the 
monomolecular chair-like G-quadruplex folding topology, during the entire course of 
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SA/MM calculations, we applied a tether force of100 kcal/Å2 to the guanine bases of 
two quartets .All resulting conformers were subsequently analyzed and 
loopnucleotides were classified on the bases of (i) glycosidic bond χ values, that is, 0° < 
χ < 90° = syn; −60° < χ < −180°= anti;136,137 90°< χ <180°and −60° < χ < 0° = s/a); (ii) the 
interatomic distance between the centroid of the ring atoms of the nucleobase of each 
loop nucleotide and the centroid of the ring atoms of the nucleobases of the two G-
tetrads (Pseudo_Atom Define command, Biopolymer Module, Insight2005). According 
to the latter parameter, the loop nucleotide was classified as “stacked” when the 
distance was <8 Å or as “not-stacked” when the distance was >12 Å, whereas a 3D 
visual inspection was needed to classify the nucleotide as “stacked” or “not-stacked” 
when the distance was between 8 and 12 Å. A nucleotide termed “stacked” presented 
at least one nucleobase atom shielded by the G-tetrads; anucleotide termed “not-
stacked” presented no atoms shielded by the G-tetrads. Occurrence rates were 
calculated for TBA and for each diastereoisomer of the new analogues TBA-T7b and 
TBA-T12b.Because all experimental data refer to the mixture of the two 
diastereoisomers, the mean of the values obtained for the two diastereoisomers was 
also calculated. 
(b) Structural and Bioinformatics Analysis. To analyze the binding modes of TBAs and 
the corresponding aptamer−thrombin interactions, all of the experimentally 
determined structures of aptamers in complex with human thrombin were 
downloaded from Protein DataBank: 1HAO, 1HAP, 1HUT, 3DD2, 3QLP, 4DIH, and 4DII. 
On the other hand, to identify the structural differences in TBA binding site between 
human and bovine thrombin, additional structures of human (PDB IDs 1HXF, 1TB6, 
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1TMT, 1TMU, 1XMN, 3HTC, and 4HTC)and bovine (PDB IDs 1HRT, 1VIT, and 3PMA) 
thrombin, sharing similar ABE I and ABE II ligands, were selected and analyzed. 
Hydrogens were added to all of the PDB structures considering a pH value of 7.4 
(Biopolymer Module, Insight 2005). All structures were superimposed by Cα atoms, 
and their sequences were extracted using the Homology module of Insight 2005 
(Accelrys). On the other hand the human (entry P00734) and bovine (entry P00735) 
prothrombin sequences were downloaded from the UniProt 
Knowledgebase(http://www.uniprot.org), and the sequence alignments were 
performed using Multiple_Sequence Alignment pulldown in theInsight 2005 Homology 
module. Moreover, for each ligand/enzyme complex, a subset around the ligands that 
consisted of all residues and water molecules having at least one atom within a 6 Å 
radius from any given ligand atom was defined. The created subsets were displayed 
and analyzed through a 3D visual inspection. The results of this analysis were 
compared with those obtained through the sequence alignments. Starting from the 
results obtained from this structural and bioinformatics analysis, to evaluate in detail 
the possibility of the residues at positions 3, 7, and 12 to interact with thrombin ABE I 
hydrophobic cleft, the solvent-accessible surface area of these nucleotides was 
evaluated by calculating the Connolly surface with a probe radius of 1.4 Å, which 
approximates the radius of a water molecule (Viewer Module, Insight 2005, Accelrys 
Software Inc.). In particular, the Connolly surface of the considered nucleotides was 
calculated for the TBA experimentally determined structures (PDBIDs 1HAO, 1HAP, 
4DIH, and 4DII) and for all conformers of TBA and new modified analogues, resulting 
from SA/MM calculations. 
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The TBA, TBA-T7b, and TBA-T12b SA/MM conformers presenting solvent-accessible 
surface areas of residues 3, 7, and 12 equal to or greater than that of the 
corresponding residue of TBA when interacting with the ABE I hydrophobic cleft in 
experimentally determined complexes (i.e., T3, 191.01 Å2; T7, 159.35 Å2; and 
T12,180.59 Å2) were selected, and their occurrence rates were calculated. Because all 
experimental data refer to the mixture of the two diastereoisomers, the mean of the 
values obtained for the two diastereoisomers was also calculated. Finally, with the aim 
to calculate the occurrence rates of bioactive conformations of residues at position 3, 
7, and 12 of TBA and new modified analogues TBA-T7b and TBA-T12b, all conformers, 
resulting from SA/MM calculations, were superimposed on the experimentally 
determined structures of TBA in complex with thrombin (PDB IDs1HAO, 1HAP, 1HUT, 
4DIH, and 4DII) by fitting heavy atoms of the guanine bases of two quartets, and the 
overlap with the residue interacting with the ABE I hydrophobic cleft (I1e24, His71, 
I1e79, and Tyr117) was evaluated. To assess the bioactive conformation of the residue 
at position 7, the orientation that allows residue 7 to be located in the same position 
of T7 of 1HAP or 1HUT crystal structure was considered (orientation II in Figure 12). 
The conformation of residues at positions 3, 7, and 12 was considered bioactive when 
the correspondent nucleobase was positioned within the ABE I hydrophobic cleft and 
presented at least one atom superimposed on T3 (PDB IDs 4DIH and 4DII) or onT7 (PDB 
IDs 1HAP and 1HUT) or on T12 (PDB ID 1HAO), respectively. Occurrence rates of 
bioactive conformations of residues at positions 3, 7, and 12 were then calculated. 
Because all experimental data refer to the mixture of the two diastereoisomers, the 
mean of the values obtained for the two diastereoisomers was also calculated. 
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Finally, with the aim to calculate the occurrence rates of bioactive conformations of 
residues at position 3, 7, and 12 of TBA and new modified analogues TBA-T7b and TBA-
T12b, all conformers, resulting from SA/MM calculations, were superimposed on the 
experimentally determined structures of TBA in complex with thrombin (PDB IDs1HAO, 
1HAP, 1HUT, 4DIH, and 4DII) by fitting heavy atoms of the guanine bases of two 
quartets, and the overlap with the residue interacting with the ABE I hydrophobic cleft 
(I1e24, His71, I1e79, andTyr117) was evaluated. To assess the bioactive conformation 
of the residue at position 7, the orientation that allows residue 7 to be located in the 
same position of T7 of 1HAP or 1HUT crystal structure was considered (orientation II in 
Figure 12). The conformation of residues at positions 3, 7, and 12 was considered 
bioactive when the correspondent nucleobase was positioned within the ABE I 
hydrophobic cleft and presented at least one atom superimposed on T3 (PDB IDs 4DIH 
and 4DII) or onT7 (PDB IDs 1HAP and 1HUT) or on T12 (PDB ID 1HAO),respectively. 
Occurrence rates of bioactive conformations of residues atpositions 3, 7, and 12 were 
then calculated. Because all experimental data refer to the mixture of the two 
diastereoisomers, the mean of the values obtained for the two diastereoisomers was 
also calculated. 
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4. Outstanding effects on antithrombin activity of modified TBA 
diastereomers containing an optically pure acyclic nucleotide 
analogue. 
Disadvantageously, since the introduced residues a or b presented a pro-chiral carbon 
(Figure 23), each obtained modified sequence existed as a mixture of two 
diastereomers.  
On these bases, the substitution of the identified key residues with a rationally 
designed and optically pure acyclic nucleoside analogue, would allow the investigation 
of the molecular bases of TBA-thrombin interaction. Here, I successful approach this 
issue by the substitution of T3 or T7 or T12 with each pure stereoisomer of the acyclic 
nucleoside c (Figure 23). 
 
 
 
Figure 23. Acyclic nucleosides mimicking thymine residue. The pro-chiral carbon of a 
and b is labelled with #. 
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4.1 Results and Discussion 
Synthesis 
The Horhota method138 was adopted to obtain the stereoselective synthesis of R and S 
enantiomers of the acyclic nucleoside c (R-c and S-c in Scheme 2 and Figure24). The R 
or S stereochemistry was attained by ring opening of the enantiomerically pure chiral 
epoxides 2 by reaction with the modified nucleobase 1 (Scheme 2). Each achieved 
molecule was converted into the corresponding phosphoramidite building block (5a,b) 
and incorporated into the TBA sequence to obtain a pool of six ONs (Table 8).  
 
 
 
Scheme 2. Synthesis of monomers 5a,b. i) 1 1.0 g (6.6 mmol), 2 (pure enantiomer R or S) 0.490 
g (6.6 mmol), potassium carbonate 0.152 g (1.1 mmol), dry DMF (24 mL), 12-18 h, 80 °C, yields 
R-c 60% and S-c 45%; ii) R-c or S-c 560 mg (2.5 mmol), 4,4'-dimethoxytrytylchloride 850 mg (2.5 
mmol), 4-dimethylaminopyridine 15 mg (0.12 mmol), pyridine (20 mL), 2.0 h, r.t., yields 85%; iii) 
4a,b 859 mg, (1.6 mmol), 2-cyanoethyldiisopropylchlorophosphoramidite 536 µL (2.4 mmol), 
DIPEA 1,7 mL (10 mmol), DCM (9 mL), 40 min, r.t., yields 99%. 
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Figure 24. CD spectra of modified acyclic nucleosides (3.6 × 10-4 M in CH3OH) R-c (positive 
spectrum) and S-c (negative spectrum). 
 
ON SEQUENCE 
TBA GGTTGGTGTGGTTGG 
TBA-R12 GGTTGGTGTGGR12TGG 
TBA-R3 GGR3TGGTGTGGTTGG 
TBA-R7 GGTTGGR7GTGGTTGG 
TBA-S7 GGTTGGS7GTGGTTGG 
TBA-S12 GGTTGGTGTGGS12TGG 
TBA-S3 GGS3TGGTGTGGTTGG 
 
 
Table 8. Modified sequences containing the c derivatives instead of a T residue. The 
incorporation of R-c or S-c stereoisomer was specified substituting, at each position, the letter T 
of the unmodified sequence for the letter R or S, respectively. 
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Structural characterization 
To probe if the introduction of R or S acyclic nucleoside c at TBA position 3, 12 or 7 
affected the overall G-quadruplex topology formed in solution, all modified TBAs were 
characterized by circular dichroism (CD) and CD melting experiments. 
As expected, in PBS and K+ (90 mMKCl, 10 mM K2HPO4, pH = 7.3) buffers, the modified 
sequences fold into G-quadruplexes having CD profiles (Figure25) and apparent 
melting temperatures (Table 9) comparable to that of TBA. Particularly, a stabilizing 
effect on the G-quadruplex structure (T = 4-5 °C) was attained by replacing T residue 
at position 3 and 12 with the R stereoisomer of c, or at position 7 with both the R and S 
stereoisomers. 
 
 
 
Figure 25.CD spectra of TBA and modified ONs in PBS (A) and K+ phosphate buffer (B). 
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ON 
 
Tm °C (± 1.0 °C) 
K+ PBS 
TBA 50 34 
TBA-R12 55 39 
TBA-R3 55 39 
TBA-R7 54 38 
TBA-S7 56 39 
TBA-S12 51 35 
TBA-S3 51 35 
 
Table 9. Tm values of TBA and modified ONs. 
 
Fibrinogen assay 
The new ONs were then evaluated for their ability to inhibit fibrinogen hydrolysis by 
fibrinogen clotting assay. The clotting of fibrinogen induced by human -thrombin was 
measured spectrophotometrically at different aptamer concentrations, following the 
increase in absorbance at 380 nm as a function of the time (Figure 26, Table 10, and 
Experimental Section). 
  
 
Figure 26.Prolonged fibrinogen clotting time (s) in presence of TBA or each active aptamer at 
different concentrations (15-100 nM). The graphics were drew from scattering curves data. 
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At 20 nM concentration, TBA and TBA-R12 prolonged the basal clotting time of 56 and 
199 s, respectively (Figure26 and Table 10). 
 
 
 
figure 27. Prolonged fibrinogen clotting time (s) in presence of  TBA, TBA-S3, or TBA-S12 at 
different concentrations (30-200 nM). The graphics were drew from scattering curves data. 
 
Thus, TBA-R12 resulted 3.5 folds more active than TBA. At the same concentration 
TBA-S12 resulted completely inactive (Figure 27, and Table 10). A similar activity trend 
was also observed between TBA-R3 and TBA-S3, being the former 1.9 folds more active 
than TBA, and the latter completely inactive (Figure26-27 and Table 10). These activity 
trends were maintained at all tested concentrations, thus evidencing a stereoselective 
interaction with the target, involving the modified T12 or T3 residues, which is crucial 
for thrombin inhibition. 
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Prolonged clotting time (s) 
ON 15 nM 20 nM 30 nM 100 nM 200nM 
TBA 24.6±2.7 56.4±5.0 159.4±11.3 256.4±19.7 N.T.a 
TBA-R12 105.4±5.7 198.9±10.1 463.4±13.6 759.6±23.8 N.T. 
TBA-R3 50.4±4.0 108.4±5.1 323.4±12.5 576.4±22.8 N.T. 
TBA-R7 49.4±3.0 89.4±3.8 167.4±6.0 304.4±19.9 N.T. 
TBA-S7 39.5±3.0 67.4±4.0 181.4±9.7 355.4±18.0 N.T. 
TBA-S12 N.A.
b N.A. 10.9±5.7 16.4±2.8 24.4±3.7 
TBA-S3 N.A. N.A 4.9±3.0 18.4±5.1 26.4±4.6 
a Not tested. b Not active. 
 
Table 10. Prolonged fibrinogen clotting times of TBA and modified ONs. Each value was 
calculated subtracting the clotting time produced by thrombin in absence of any inhibitor (i.e., 
25.6 ± 1.5 s) from that measured in the presence of the aptamer. 
 
Molecular modelling studies 
The resulting SARs of the new modified ONs were rationalized by aid of molecular 
modelling studies (see Experimental Section for details). As observed by Feigon et al. 
and confirmed by X-ray data,88,89 due to the TBA symmetry, residues T3 and T12 
occupy equivalent positions with respect to the G quartets, and, by consequence, their 
binding clefts at thrombin Exosite I (ABE I) can be “exchanged” by rotating the 
structure 180° around the Y-axis (binding modes III and IV in Figure 12 and 28). 
Conversely, the TBA symmetry is lost when either T3 or T12 is modified and, in 
particular, TT loops are no more equivalent. In our case, monomer c is characterized by 
i) higher conformational flexibility and ii) greater steric hindrance with respect to 
thymidine. Our computational results indicated that TBA-R3 and TBA-R12, which 
preserved the stereochemistry of the thymidine residue, could easily adopt bioactive 
conformation of the TT loops (Figure29a). 
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Figure 28. X-ray structures of the complex between TBA and human α-thrombin presenting 
aptamer TT loops interacting with thrombin ABE I. (a) and (c): binding mode III; PDB structure 
1HAO (TBA carbons = cyan). (b) and (d): binding mode IV; PDB structure 4DIH (TBA carbons = 
yellow). Heteroatoms are coloured as follows: O = red; N = blue; P = magenta.  Thrombin ABE I 
is shown as green ribbon. 
 
 
 
Figure 29. (a) TBA-R12 (carbons = orange) and (b) TBA-S12 (carbons = pink) superimposed on 
the bioactive conformation of TBA in complex with thrombin (carbons = cyan; PDB ID: 1HAO). 
Heteroatoms are coloured as follows: O = red; N = blue; P = magenta. Thrombin ABE I is shown 
as green ribbon. Hydrogens are omitted with the exception of those present on the modified 
residue chiral carbon (R-c12 and S-c12) and on TBA T12 C4’. The position of P13 is highlighted 
by a dashed circle and an arrow. 
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The significant increase in inhibitory activity of TBA-R3 and TBA-R12 with respect to 
TBA indicates the presence of additional favourable hydrophobic contacts with the 
protein in, at least, one of the TT loops binding clefts. On the contrary, when the 
stereochemistry of c is inverted with respect to the C-4' carbon atom of the natural 
counterpart (i.e., TBA-S3 and TBA-S12), it is not possible for both binding sites, TT 
loops to properly place at their thrombin whatever binding mode is assumed. Indeed, 
although monomers c are characterized by higher structural flexibility with respect to 
thymine, TT loops conformation is highly limited by the stacking of T4 and T13 on the 
G-quartet. Therefore, when the nucleobase analogue moiety of c in TBA-S3 and TBA-
S12 projects in the same direction as the nucleobase of T3 and T12 in the bioactive 
conformation of TBA87-89the succeeding phosphate group (i.e., P4 or P13) is forced to 
distance itself from the G-quartet plane, likely causing steric clashes with the protein 
backbone (Figure 29b). 
Another important outcome which emerged from our results is the higher inhibitory 
activity of TBA-R12 compared to TBA- R3. 
In this case, the lack of structural symmetry does not explain the difference in the 
activities of TBA-R12 and TBA-R3, since the same TT loops binding mode at thrombin 
ABE I could be achieved for both analogues by rotating the structure by 180° 
(Figure28). This indicates that, although TT loops-ABE I interaction is necessary for 
biological activity, it is not the only factor able to modulate the inhibition of thrombin. 
Further considerations can be done taking into account the results obtained with 
aptamers modified at position 7 of the TGT loop. The substitution of T7 with the R or S 
enantiomer of c produced almost equally active aptamers (Figure 23 and Table 10). On 
one hand, the lack of significant stereo selectivity of action between the two 
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diastereomers would suggest that the TGT loop is not directly involved in thrombin 
binding. On the other hand, TBA-R7 and TBA-S7 showed increased inhibitory activity 
(either with respect to TBA, and to previously developed analogues bearing the 
monomer b)139 which cannot be ascribed to the increased stability of the quadruplex 
structure (Tm (PBS) TBA = TBA-T7b139 = 37.5 °C; TBA-R7 = 38 °C; TBA-S7 = 39 °C), thus 
supporting the possible direct involvement of the TGT loop in thrombin 
inhibition.87,88,139,121 Our molecular modelling studies showed that, contrarily to what 
observed for the more rigid TT loops, the higher conformational flexibility of the TGT 
loop allows both c enantiomers to adopt the bioactive conformation87,88of the residue 
at position 7, without affecting the height of P7-P9 phosphate groups from the 
underlying G tetrad plane (Figure 30). In particular, most TBA-R7 conformers 
presented, similarly to TBA bioactive conformation, G8 stacked on the G1-G6-G10-G15 
quartet and T9 pointing outside (Figure 30a). 
 
 
Figure 30. (a) TBA-R7 (carbons = orange) and (b) TBA-S7 (carbons = pink) superimposed on the 
bioactive conformation of TBA in complex with thrombin (carbons = green; PDB ID: 1HAP). 
Heteroatoms are coloured as follows: O = red; N = blue; P = magenta. Thrombin ABE I is shown 
as green ribbon. Hydrogens are omitted with the exception of those present on the modified 
residue chiral carbon (R-c12 and S-c12) and on TBA T7 C4’. 
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The opposite trend was observed for TBA-S7 (Figure. 30b). Analyzing these results at 
the light of reported TBA-thrombin binding modes and X-ray structures,87-89 it resulted 
that the two different TGT loop conformations can assume the binding modes I and II 
represented in Figure12.  
Taken together, results indicate that either TT loops and TGT loop are involved in 
thrombin inhibition, but playing different roles. The TT loops are necessary for high 
affinity thrombin inhibition by establishing a stereoselective interaction with the 
protein through residues at position 3 and 12. On the contrary, the TGT loop seems to 
be involved in less specific interactions with thrombin. Indeed, the TGT loop is not 
sufficient for significant thrombin binding when the binding ability of the TT loops is 
impaired (TBA-S3 and TBA-S12). Moreover, no significant stereoselectivity of action 
was observed between  TBA-R7 and TBA-S7. The results of our molecular modelling 
studies suggest that the flexibility of the TGT loop, together with the availability of 
multiple aptamer-protein binding modes, likely contribute to the observed lack of 
stereoselectivity between TBA-S7 and TBA-R7. Anyway, a single modification of the 
TGT loop at position 7 can enhance thrombin inhibition, through a still undefined 
molecular mechanism. A fascinating hypothesis, supported by some available X-ray 
data,87,88 is that the high affinity binding of the TT loops could drive the interaction of 
the TGT loop with a second unit of thrombin, and this, in turn, due to thrombin 
allostery, somehow favors the binding of another TBA monomer in a cooperative 
mechanism. 
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4.2 CONCLUSIONS 
The results presented herein, clearly establish the role of loop conformational 
preferences on the overall TBA-thrombin complexes and illustrate how a 
stereochemical modification can impact on aptamer-protein recognition.  
Furthermore, since T residues are often loop components of aptamers, our analyses 
can be widely reproduced in other cases, using the R/S nucleoside derivatives c as two 
simple alternatives for T residue, to acquire and/or refine structure-activity 
relationship between aptamers and their targets. 
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4.3 EXPERIMENTAL SECTION 
Materials and methods 
Chemicals and anhydrous solvents were purchased from Fluka-Sigma-Aldrich. TLCs 
were run on Merck silica gel 60 F254 plates. Silica gel chromatography was performed 
by using Merck silica gel 60 (0.063–0.200 mm). The API 2000 (Applied Biosystem) mass 
spectrometer was used to perform the analyses of the intermediates and the 
monomer. Melting points of intermediates R-c and S-c were measured using Buchi 
Melting Point B-540. NMR experiments were recorded using Varian Mercury Plus 400 
MHz spectrometer and processed using the Varian VNMR software package. Reagents 
and phosphorammidites for DNA syntheses were purchased from Glenn Research. ONs 
syntheses were performed on a PerSeptiveBiosystem Expedite DNA synthesizer. HPLC 
analyses and purifications were carried out using a JASCO PU-2089 Plus HPLC pump 
equipped with a JASCO BS-997-01 UV detector. CD experiments were performed on a 
JASCO 715 spectropolarimeter equipped with a PTC-348 temperature controller. The 
fibrinogen assay was performed using a JASCO 530 UV spectrophotometer equipped 
with the PTC-348 temperature controller. []D138 value for R-c and S-c were 
determined using JASCO P-2000 Polarimeter. Molecular modelling calculations were 
performed on SGI Origin 200 8XR12000 and E4 Server Twin 2 x Dual Xeon 5520, 
equipped with two nodes. Each node was 2 x Intel Xeon QuadCore E5520, 2.26 GHz, 36 
GB RAM. The molecular modelling graphics were carried out on SGI Octane 2 
workstations. 
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Synthesis procedure 
Synthesis of monomers 4a and 4b. 6,7-dihydro-1H-cyclopenta[d]pyrimidine-
2,4(3H,5H)-dione (1). 1 was obtained as previously reported by Takaya et al.140 Briefly, 
a solution of ethyl-2-oxocyclopentanecarboxylate (10 g, 64.0 mmol), urea (5.76 g, 96 
mmol) and HCl (37% w/w, 0.096 mL) in EtOH (20 mL) was refluxed for 3h. After 
filtration, the collected white solid was suspended in 5% NaOH (24 mL) and refluxed 
for 1h. The reaction was cooled to room temperature and the solid 1 collected by 
filtration and dried (yields 60%; Rf 0.42 in 9:1 CH2Cl2:CH3OH, v/v). 
1H NMR (400 MHz, mixture of CD3OD and CDCl3): δ 4.00 (bs, 2H), 3.62 (m, 4H), 3.03 (t, 
J = 7.3 Hz, 2H), 2.67 (t, J = 7.3 Hz, 2H), 2.10 (q, J = 7.3 Hz, 2H).  
13C NMR (400 MHz, mixture of CD3OD and CDCl3): δ 166.3, 155.2, 147.3, 113.4, 34.8, 
30.5, 18.0.  
ESI Mass (positive mode): calculated 152.1; found 153.1 [M+H]+, 175.1 [M+Na]+. 
 
1-(2,3-dihydroxypropyl)-6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione 
[S-c or R-c]138. A mixture of compound 1 (1 g, 6.6 mmol) and anhydrous potassium 
carbonate (0.152 g, 1.1 mmol) in dry DMF (24 mL) were heated at 80 °C for 5 min. 
Compound 2 (pure enantiomer R or S) (0,490 g, 6,6 mmol) was than added. The 
reaction mixture was stirred at 80 °C for 18 h under argon. The solution was 
concentrated under reduced pressure and the residue purified by column 
chromatography on silica gel eluted with 95:5 CH2Cl2/CH3OH, to give S-c or R-c as white 
solids (yields S-c 45%, R-c 60%). Figure 24 reports the CD profiles of each pure 
enantiomer S-c or R-c. 
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S-c 1H NMR (400 MHz, pyridine-d6): δ 4.66 (m, 1H, CHOH), 4.45 (dd, 1H, J1 = 14.0 Hz, 
J2 = 3.6 Hz, CHaHbOH), 4.08 (d, 2H, J = 5.2 Hz, CH2N), 3.93 (dd, 1H, J1 = 14.0 Hz, J2 = 
8.6 Hz CHaHbOH), 3.17 (m, 1H, CHaHb), 2.83 (m, 1H, CHaHb), 2.69 (m, 2H, CH2), 1.82 
(m, 2H). 
S-c 13C NMR (100 MHz, CD3OD): δ 163.0, 160.4, 153.2, 111.6, 69.4, 63.9, 32.6, 27.0, 
21.0.  
ESI Mass (positive mode): calculated 226.1; found 227.1 [M+H]+, 249.1 [M+Na]+. 
[]D138= –51.4. 
S-c in crystalline state was obtained from CH3COCH3: CH3OH (99:1, v:v). Measured 
melting point was in the range 141-143 °C. 
R-c 1H NMR (400 MHz, pyridine-d6): δ 4.66 (m, 1H, CHOH), 4.45 (dd, 1H, J1 = 14.0 Hz, 
J2 = 3.6 Hz, CHaHbOH), 4.08 (d, 2H, J = 5.2 Hz, CH2N), 3.93 (dd, 1H, J1 = 14.0 Hz, J2 = 
8.6 Hz CHaHbOH), 3.17 (m, 1H, CHaHb), 2.83 (m, 1H, CHaHb), 2.69 (m, 2H, CH2), 1.82 
(m, 2H). 
R-c 13C NMR (100 MHz, CD3OD) 163.0, 160.4, 153.2, 111.6, 69.4, 63.9, 32.6, 27.0, 21.0.  
ESI Mass (positive mode): calculated 226.1; found 227.1 [M+H]+, 249.1 [M+Na]+. 
[]D138 = + 54.3.  
R-c in crystalline state was obtained from CH3COCH3: CH3OH (99:1, v:v). Measured 
melting point was in the range 141-143 °C. 
1-(2,4-dioxo-3,4,6,7-tetrahydro-2H-cyclopenta[d]pyrimidin-1(5H)-yl)-3-((3-
methoxyphenyl)(4-methoxyphenyl)(phenyl)methoxy)propan-2-yl-P-2-cyanoethyl-
N,N-cianopropylphosphonamidate 5a and 5b. Compound R-c or S-c (560 mg, 2.5 
mmol), 4,4’-dimethoxytrytyl chloride (850 mg, 2.5 mmol) and 4-dimethylaminopyridine 
(15.0 mg, 0.12 mmol) were dissolved in dry pyridine (20 mL). The resulting solution 
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was stirred at room temperature under argon for 1.5 h. Dry methanol (200 L) was 
then added to quench the reaction. After 30 min under stirring the solution was 
concentrated under reduced pressure and the residue purified by column 
chromatography on silica gel (eluted with 50:50:1 CH2Cl2/CH3OH/Et3N) to give 
monodimethoxytritylated derivative 4a or 4b as a white foam (1.16 g, 85% yield from 
each c stereoisomer; Rf 0.7 eluted with CH2Cl2/CH3OH 1:1 v/v). The solid (859 mg, 1.6 
mmol) was dried in vacuum overnight before being dissolved in anhydrous DCM (9 mL) 
and diisopropylethylamine (1.7 mL, 10 mmol) under argon. 536 L of β-
cyanoethyldiisopropylchlorophosphoramidite was then added (2.4 mmol). After 40 
min the reaction was quenched by addition of dry methanol (100 L), diluted with 
ethyl acetate (15 mL) and finally washed with 10% sodium carbonate solution (15 mL) 
and brine (15 mL). The organic layer was dried on magnesium sulphate and 
concentrated in vacuum. The residue was purified by silica gel chromatography eluted 
with DCM, ethyl acetate, triethylamine (80:10:10). The fractions containing the 
product were collected and concentrated under vacuum yielding phosphoramidite 
building block 5a [from R-c] or 5b [from S-c] as a white foam (1.15 g, 99% yield; Rf 0.75 
in CHCl3/MeOH/TEA 97:3:0.05 v/v).  
1H NMR (400 MHz, CDCl3): δ 7.42-7.17 (9H), 6.90 (4H), 4.18 (m, 1H), 4.03 (m, 1H), 3.78 
(s, 6H), 3.90-3.60 (m, 3H), 3.22 (m, 1H), 3.19 (m, 1H), 3.06 (m, 1H), 2.90 (m, 1H), 2.80–
2.60 (m, 2H), 2.48 (m, 2H), 2.38 (m, 2H), 2.12 (m, 2H), 1.2-1.0 (m, 12H). 
13C-NMR (100 MHz, CDCl3): δ 161.4, 158.6, 153.2, 147.3, 139.4, 135.1, 130.3, 129.1, 
127.8, 127.7, 127.1, 113.1, 64.4, 60.4, 55.2, 47.3, 33.6, 29.7, 27.6, 20.9, 19.3, 17.3. 
ESI Mass (positive mode): calculated 728.3; found 729.3 [M+H]+, 751.3 [M+Na]+. 
 
81 
 
Synthesis of oligomers. 
See section 3.4 
 
CD experiments 
To perform the CD experiments on modified nucleosides R-c and S-c, each compound 
was dissolved in CH3OH at the final concentration of 3.6 × 10
-4 M, the two solutions 
were equilibrated for 10 min at r.t. and then the CD spectra were registered.  
To perform the CD experiments on modified TBA sequences, each ON was dissolved in 
the potassium (90 mMKCl, 10 mM KH2PO4, pH 7.4) or PBS (90 mMKCl, 10 mM KH2PO4, 
pH 7.4) phosphate buffer at the final ON concentration of 2.0 × 10-5 M and submitted 
to the annealing procedure (heating at 90 °C and slowly cooling at r.t.). Before each 
experiment, the samples were equilibrated at 10 °C for 30 min. CD spectra were 
recorded from 200 to 400 nm at 100 nm/min scanning rate, 16 s response, 1.0 nm 
bandwidth. Each CD profile was obtained by taking the average of three scans from 
which the spectrum of background buffer was subtracted.  
CD melting-folding curves were obtained by monitoring the variation of absorbance at 
295 nm from 10 to 90 °C and vice versa in K+ phosphate buffer (80 mMKCl, 20 mM 
KH2PO4 pH= 7.4) and PBS (147 mMNaCl, 20 mM NaH2PO4, 23 mM KCl, pH = 7.4) at [ON] 
= 2.0 × 10-5 M using a 1.0 cm cuvette. Two melting-folding experiments for each ON 
were recorded at 0.5 °C/min and 1.0 °C/min heating-cooling rate. No substantial 
differences between melting and cooling curves were detected. Both types of curves 
resulted independent from temperature scanning rate (0.5 °C/min or 1.0 °C/min).  
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Fibrinogen clotting assay 
The fibrinogen clotting times were measured spectrophotometrically.141 ONs were 
incubated for 1 min at 37 °C in 1.0 mL of PBS containing 2.0 mg/mL of fibrinogen 
(Fibrinogen from human plasma, F 3879, Sigma-Aldrich) in a PMMA cuvette (vol. 1.5 
mL, c.o. 1 cm, Brand). 100 μL of human thrombin (10 NIH per mL; Sigma-Aldrich, 
T8885, human thrombin suitable for thrombin time test) was then added to the 
solution containing the fibrinogen and the ON. The time required to fibrin 
polymerization was determined from UV scattering curve, registered as a function of 
the time (wavelength fixed at 380 nm) in the presence of each ON. Each curve was 
determined in triplicate at different concentrations. The clotting time value reported 
as M ± SE, was derived as the maximum of the second derivative of each scattering 
curve. The basal clotting time was determined by measuring the UV scattering as a 
function of the time produced in the absence of any ONs. The 15-mer 
GTGTGTGTGTTGTGT was used as negative control. In the absence of any inhibitor, the 
clotting time value was 25.6 ± 1.5 s. The prolonged fibrinogen clotting times of TBA 
and modified ONs were calculated by subtracting the clotting time produced by 
thrombin in the absence of any inhibitor from that measured in the presence of the 
aptamer. 
Molecular modeling.  
Experimentally determined structures of TBA alone (PDB ID: 148D) and in complex 
with thrombin (PDB IDs: 1HAO, 1HAP, 1HUT, 4DIH, and 4DII) were downloaded from 
Protein Data Bank (PDB, http://www.rcsb.org/pdb/) and analyzed using the Homology 
module of Insight 2005 (Accelrys Software Inc., San Diego, CA). Hydrogens were added 
to all these structures considering a pH value of 7.4 (Biopolymer Module, Insight 2005). 
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Since the replacement of T3, T7 and T12 residues with nucleoside c produced 
diastereomers characterized by S or R configuration at the acyclic linker, for each new 
TBA analogue, the two diastereomers were built by modifying the experimentally 
determined structure of TBA in complex with thrombin (PDB ID: 1HAO; Insight2005 
Builder module). Atomic potentials and charges were assigned using the CVFF force 
field.134 
The conformational space of the new modified analogues was sampled through 200 
cycles of simulated annealing (SA) followed by molecular mechanics (MM) energy 
minimization. During the SA procedure, the temperature is altered in time increments 
from an initial temperature to a final temperature by adjusting the kinetic energy of 
the structure (by rescaling the velocities of the atoms). The following protocol was 
applied: the system was heated to 1000 K over 2000 fs (time step of 1.0 fs); a 
temperature of 1000 K was applied to the system for 2000 fs (time step of 1.0 fs) to 
surmount torsional barriers; successively, temperature was linearly reduced to 300 K 
in1000 fs (time step of 1.0 fs). Resulting conformations were thensubjected to MM 
energy minimization within Insight 2005 Discover_3 module (CVFF force field) until the 
maximum rms derivative was less than 0.001 kcal/Å, using conjugate gradient135 as the 
minimization algorithm. In order to reproduce the physiological environment where 
these molecules act and, to evaluate the effects of the implicit solvent, we sampled the 
conformational space through the combined procedure of SA/MM calculations, using 
the dielectric constant of water (ε = 80*r). Moreover, in order to allow a complete 
relaxation of the structures preserving the monomolecular chair-like G-quadruplex 
folding topology, during the entire course of SA/MM calculations, we applied a tether 
force of 100 kcal/Å2 to the guanine bases of the two quartets.  
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Resulting conformers were analyzed and loop nucleotides were classified on the bases 
of: (i) glycosidic bond χ values, i.e., 0° < χ < 90° = syn; -60° < χ < -180°= anti;136,137 90°< χ 
<180° and -60° < χ < 0°  = s/a); (ii) the interatomic distance between the centroid of the 
ring atoms of the nucleobase of each  loop nucleotide and the centroid of the ring 
atoms of the nucleobases of the two G-tetrads (Pseudo_Atom Define command, 
Biopolymer Module, Insight 2005). When the distance was <8 Å, the loop nucleotide 
was classified as “stacked”, when the distance was  >12 Å it was classified as “not-
stacked”. A 3D visual inspection was used to classify the nucleotide when the distance 
was included between 8 Å and 12 Å. In any case, a “stacked” nucleotide presented at 
least one nucleobase atom under the G-tetrads.  
New modified TBA conformers, resulting from SA/MM calculations, were 
superimposed on the experimentally determined structures of TBA in complex with 
thrombin (PDB IDs: 1HAO, 1HAP, 1HUT, 4DIH and 4DII) by fitting heavy atoms of the 
guanine bases of two quartets, and the overlap with the residues interacting with 
thrombin ABE I was evaluated. All possible TBA binding modes (Figure 12) were 
considered. For each aptamer/enzyme complex a subset around the ligand including 
all protein and water molecules having at least one atom within a 6 Å radius from any 
given aptamer atom was defined. The created subsets were displayed and analyzed 
using Insight 2005 Biopolymer and Homology modules (Accelrys Software Inc., San 
Diego, CA). 
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5. 5-HYDROXYMETHYL-2'-DEOXYURIDINE RESIDUES IN TBA: 
IMPROVING THE BIOLOGICAL ACTIVITY BY A TINY CHEMICAL 
MODIFICATION. 
 
In order to acquire new data about the importance of each residue of the TBA loop 
region (and, in case, by the single chemical groups) in both thermal stability and TBA-
thrombin recognition and, particularly, to discriminate the contributions of the ionic 
and hydrophobic components in the interaction, I have undertaken a systematic 
investigation using the single-base substitution approach by thymine analogues 
containing tiny chemical modifications. Particularly, here I describe structural and 
biological properties of new TBA derivatives (Table 11) in which single thymines have 
been replaced by a natural occurring unusual base (5-hydroxymethyl-2'-deoxyuridine, 
hmU, Figure31)142 that differs from the canonical thymine only in the presence of an 
hydroxyl group on the exocyclic carbon. This small modification has been selected in 
order to significantly decrease the base hydrophobicity avoiding, at the same time, 
severe changes of the positions of the phosphate groups, that are responsible for the 
ionic interactions with the thrombin. 
 
 
 
 
 
Table 11. Aptamers investigated and their melting temperatures (Tm). H = 5-hydroxymethyl-2'-
deoxyuridine. Tm = Tm (mod. aptamer) - Tm (TBA). N.a. = not applicable 
Name Sequence (5'-3') Tm (°C) Tm 
TBA GGTTGGTGTGGTTGG 50 n.a. 
H3 GGH3TGGTGTGGTTGG 51 +1 
H4 GGTH4GGTGTGGTTGG 50 0 
H7 GGTTGGH7GTGGTTGG 52 +2 
H9 GGTTGGTGH9GGTTGG 54 +4 
H12 GGTTGGTGTGGH12TGG 50 0 
H13 GGTTGGTGTGGTH13GG 49 -1 
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Figure 31.  Schematic representation of the TBA G-quadruplex (left) and chemical structure of 
hmU (right) 
 
Collected CD, CD melting, NMR and biological data allowed us to obtain further 
information about the relevance of some TBA-thrombin contacts for the anticoagulant 
activity. 
 
5.1 RESULTS AND DISCUSSION 
 
CD and CD melting 
Circular dichroism has been utilized to compare the general conformation assumed by 
natural TBA and the modified oligonucleotides containing a hmU residue. The CD 
spectrum of TBA shows two positive bands at 247 and 295 nm and a negative band at 
266 nm. This CD profile is typical of a G-quadruplex structure in which anti and syn 
guanosines alternate along the strands.  
The CD spectra obtained for the modified analogues could conveniently be divided in 
two groups. The first one includes ODNs H3, H7, H9 and H12, showing profiles strictly 
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similar to that of TBA with only a slight intensity decreasing (Figure32, Panel A). In 
contrast, the second group (ODNs H4 and H13), shows CD profiles quite different in 
the region 230-280 nm and a remarkable decreasing of the intensity of the band at 292 
nm, compared to the TBA (Figure 32, Panel B).  
 
 
 
Figure 32. CD spectra at 5°C of (A) H3 (blue), H7 (black), H9 (light blue), H12 (orange); (B) H4 
(green), H13 (purple) in comparison to TBA (red) at 100 µM ODN strand concentration in a 
buffer solution 10 mM KH2PO4/K2HPO4, 70 mM KCl (pH 7.0). 
 
Notably, CD spectra of H4 and H13 are also characterized by the absence of the 
negative peak at 266 nm. These data would suggest that H4 and H13 are able to form 
additional conformations beside that distinctive of TBA. In order to get further data 
about this point, in different experiments, CD spectra of all the modified ODNs have 
been recorded after heating at 90°C, followed by rapid cooling. While no significant 
differences between the two CD profiles could be detected for ODNs H3, H7, H9 and 
H12, noteworthy changes in the CD profiles of the other modified ODNs are clearly 
observable (figure 33). Particularly, the CD profile of H13 obtained in these conditions 
is similar to that of the TBA, but it significantly changes when the sample is left to 
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equilibrate (Figure 32, Panel B), thus confirming the presence of minor alternative 
conformations at the equilibrium.  
 
 
Figure 33. CD spectra at 5°C of modified TBA at 100 µM ODN strand concentration in a buffer 
solution 10 mM KH2PO4/K2HPO4, 70 mM KCl (pH 7.0) submitted to different annealing 
procedure (heating at 90°C and slowly cooling at room temperature: green lines; heating at 
90°C and quickly cooling at 5°C: blue lines). 
 
Interesting data have been acquired also from estimation of the thermal stabilities 
obtained by CD melting measurements, in comparison to TBA. While none or only 
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modest improvements in the Tm could be observed for ODNs H3, H4, H7, H12 and 
H13, a noteworthy increment (+4°C) of the Tm has been detected for H9 (Table 11), 
despite the small structural difference between the canonical thymine present in TBA 
and the modified base hmU incorporated in H9. Based on previously reported 
NMR143,144 and crystallographic data,88,89,91 these results were expected to some 
extent. In fact, residues T3, T7 and T12 point out of the G-quadruplex core and toward 
the solvent. The substitution of a T with hmU residue at any of these positions might 
explain such positive effects, since the hydroxyl group of hmU is able to form 
favourable polar interactions with the surrounding water molecules. On the other 
hand the negative effect produced by the introduction of hmU at 4 and 13 positions 
might be explained by considering the potential interference of the hydroxyl group on 
the T4:T13 hydrogen bonding interaction, thus reducing its contribution to the thermal 
stability of the original structure and then, inducing the formation of alternative 
conformations. Concerning H9, its higher thermal stability compared to TBA, 
represents a noteworthy exception, particularly taking into account previous single-
base substitution investigations involving T9 residue, in which only G-quadruplex 
structures strongly less stable than TBA have been obtained.107,121,122,145 
 
NMR 
The one-dimensional 1H-NMR spectra (700 MHz, T = 25°C) of all the modified thrombin 
aptamers (Figure 34) in the buffer conditions used here (see experimental section for 
details) show the presence of eight well-defined signals in the region 11.5–12.3 p.p.m., 
attributable to imino protons involved in Hoogsteen hydrogen bonds of at least two G-
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quartets and, moreover, fifteen main signals in the aromatic region, due to the 
presence of nine guanine H8 and six thymine H6 protons.  
With the exclusion of some weak resonances observable in the aromatic region, due to 
very minor conformations also present in solution (probably attributable to the 
unfolded species, since their relative intensities turned out to be sensitive to 
temperature changes), the simple appearance of 1D spectra of all the samples 
indicates that the modified oligomers form mainly a single well-defined hydrogen-
bonded conformation. 
In the cases of H4 and H13, however, it is to report the presence of significant amounts 
of unfolded species in solution at 25°C and/or alternative conformations that, together 
with the lowest affinity for thrombin (vide infra), deterred us from further NMR 
investigations. On the contrary, the proton spectra of the modified aptamers H3, H7, 
H9, H12 were assigned on the basis of NOESY and TOCSY data obtained at 700 MHz, 
25°C. The intensities of NOESY crosspeaks between the aromatic base proton and 
sugar H1' resonances of the modified thrombin aptamers indicate that four Gs (G1, G5, 
G10 and G14) adopt syn glycosidic conformations while five Gs (G2, G6, G8, G11 and 
G15) adopt anti conformations, where the H8 resonances of the syn G residues are 
upfield shifted with respect to those of the anti ones.85,86 On the other hand, all of the 
thymines show anti glycosidic conformations. 
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Figure 34. Aromatic and imino protons regions of the 1H-NMR spectra (700 MHz, T=25°C) of the 
hmU containing modified TBA and their natural counterpart in 10 mM KH2PO4/K2HPO4, 70 mM 
KCl and 0.2 mM EDTA (pH 7.0). 
 
The crosspeak patterns indicate that four anti-Gs (G2, G6, G11 and G15) have classical 
H8/H2'–H2'' sequential connectivities to 5' neighboring syn-Gs (G1, G5, G10 and G14, 
respectively), indicating that the subunits 5'-G1G2-3', 5'-G5G6-3', 5'-G10G11-3' and 5'-
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G14G15-3' are involved in the formation of a four-stranded helical structure. In 
summary, as observed for the unmodified TBA, there are 5'-GsynGanti-3' steps along 
each strand of the two quartets86 and moreover, the entire pattern of NOEs observed 
for all cited Gs indicates that the backbone conformations of these tracts resemble 
those of the unmodified TBA possessing a right-handed helix structure. The alternation 
of syn and anti G residues within each strand suggests that, as TBA, all the modified 
oligomers fold into a monomolecular foldback quadruplex, characterized by two G 
tetrads.  
Since interresidue NOEs are typically weak for 5'-anti-syn-3' steps, there are two 
strings of 5'-GGTT-3' connectivities, namely 5'-G1G2T3T4-3' and 5'-G10G11T12T13-3' 
(where syn G residues are designated by G). Further additional connectivities are 
present for the segments 5'-G5G6T7G8T9-3' and 5'-G14G15-3' and the corresponding 
stretches, identified on the basis of anti-anti connectivities. There are no sequential 
connectivities between the 3'-side thymines in each loop (T4, T9, and T13) and the 
following syn-G. 
These two- to four-residue stretches of sequential connectivities were arranged taking 
into account the primary sequence and the information in long-range NOE 
connectivities. 
As in the case of the parent TBA, for all the modified aptamers studied, there is a 
number of NOE connectivities observed between residues not adjacent in sequence. In 
particular, NOEs are present between H8 of G2 and methyl, H2' and H2'' of T4 and 
between H8 of G11 and methyl, H2' and H2'' of T13. Complementary information is 
provided by the NOEs from the methyl of T4 with Hl', H2' and H2'' of G2 and from the 
methyl of T13 with Hl', H2' and H2'' of G11. This collection of NOEs places T4 and T13 
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residues close to the G2-G5-G11-G14 tetrad. There are also NOE connectivities 
between H8 of G8 and Hl', H2' and H2'' of G6 and between H1' of T9 and H8 of G15, 
thus indicating that G8 and T9 residues in the TGT loop are near to the G1-G6-G10-G15 
tetrad. This collection of NOEs showed that, as strongly suggested by the CD data, all 
the modified aptamers investigated by NMR adopt quadruplex structures strictly 
resembling the parent one.  
However, as far as H9 is concerned, it is noteworthy the presence of two further 
unusual features, in comparison with the parent TBA and the other modified 
aptamers: 1) a considerable downfield shift of H6 proton of the H9 residue and, 2) an 
additional NOE between this proton and H2' of G10 (Figure 35). These data could be 
tentatively explained by considering that the substitution of a methyl group with a 
hydroxymethyl one in H9 would make possible the occurrence of an H-bond between 
the –CH2OH on C-5 of T9 and the N3 of G8. The validity of this consideration is 
corroborated by the molecular model of H9 (Figure 36) in which, beside the formation 
of the H-bond, a more effective stacking of the residues H9 and G8 with the underlying 
tetrad is also observed, in comparison with the unmodified aptamer.The presence of a 
hydrogen bond involving H9 and G8 facilitating the stacking of these residues with the 
underlying tetrad G1-G6-G10-G15, positively contributes to the thermal stability. 
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Figure 35. Expanded 2D NOESY spectrum of H9 (700 MHz; 25°C; strand concentration 3 mM; 10 
mM KH2PO4/K2HPO4, 70 mM KCl and 0.2 mM EDTA, pH 7.0 in H2O/D2O 9:1; total volume 0.6 
mL; mixing time 180 ms) correlating bases H8/H6 and sugar protons. The red box highlights the 
NOE H6H9/H2'G10 (see text for details). 
 
 
 
 
 
 
 
95 
 
 
Figure 36. Molecular models of the quadruplexes formed by H9 (left) and the unmodified TBA 
(right). The structures are oriented with the 5’- and 3’-ends upward (carbons, green; nitrogens, 
blue; oxygens, red; hydrogens, white; phosphorus, pink). The ODNs backbone was rendered as 
colored ribbon.  
 
Fibrinogen Assay  
In order to evaluate their ability to compete with fibrinogen for thrombin anion 
binding exosite 1 (ABE I) the modified aptamers were subjected to purified fibrinogen 
clotting assay. The thrombin-induced clotting of fibrinogen was measured 
spectrophotometrically,141 following the increase in absorbance at 380 nm as a 
function of time (Figure 37). 
All modified sequences showed an inhibitory efficiency lower than the parent TBA at 
the explored concentration range. Particularly, the ODNs H4 and H13 resulted unable 
to significantly prolong the basal clotting time. Indeed, also when present in the test at 
the highest explored concentration (60 nM), the derived clotting time value was 
roughly that obtained in absence of any inhibitor. Concerning the other four modified 
aptamers the loss of affinity compared to TBA, has been of a lesser extent for the two 
aptamers containing the modified residue at TGT loop, namely H7 and H9, with respect 
to those modified at one of the TT loops, namely H3 and H12 (Figure 36). These results 
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have revealed important structure-activity relationships. Differently from other 
clotting tests performed using plasma samples, in fibrinogen assay, only thrombin and 
fibrinogen or thrombin, fibrinogen and an inhibitor are present.  
 
 
Figure 37. Prolonged fibrinogen clotting times measured in PBS buffer in presence of fibrinogen 
(2mg/mL), thrombin (1,0 NIH) and TBA or each modified ODN at different concentrations. 
 
Consequently, the interferences produced by other plasma components (such as other 
thrombin substrates or thrombin precursors) can be excluded and the possible 
prolongation of the clotting time value can be directly attributed to the competition of 
the aptamer with fibrinogen for the binding to the thrombin. Data shown in Figure 37 
evidence that the loss of the original G-quadruplex conformation causes to become H4 
and H13 unable to inhibit fibrin clot formation, at any concentration in the explored 
range 20-60 nM. This result is in agreement with other previously reported 
studies,122thus confirming the relevant role of T4 and T13 both for G-quadruplex 
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stability and thrombin inhibitory activity of TBA. However, despite the resemblance of 
their quadruplex structures to TBA, also the other four aptamers H3, H7, H9 and H12 
have shown a general loss of the inhibitory efficiency (Figure 37) respect to TBA, more 
marked in the cases of H3 and H12. Recently reported crystal structures of TBA-
thrombin complexes showed that the TT loops of the G-quadruplex bind the thrombin 
ABE 1, through residues T3 and T12 interacting with two hydrophobic clefts of the 
protein, whereas the TGT would be excluded from any interactions with thrombin.89,91 
Taking into account this datum, the introduction of a hmU residue at T3 or T12 
positions could produce a steric clash with at least one of the hydrophobic cleft, thus 
causing the partial loss of the inhibitory activity. Importantly, the fibrinogen assay has 
shown a negative effect on clotting inhibition also in the cases of H7 and H9, although 
in a lesser extent. These data are in agreement with results obtained in previous 
studies,121,122,139,143 and support the hypothesis that, beside the TT loops, also the TGT 
loop would be involved in the binding of TBA to thrombin. 
 
PT assay 
Finally, using the PT test, we have also valued the ability of each modified aptamer to 
inhibit the fibrin clot formation in plasma samples (Figure 38). As expected, at all 
explored concentrations H4 and H13 are unable to prolong the basal PT value 
significantly. Nevertheless, despite the negative results of the fibrinogen assay, we 
observed that, at all tested concentrations of aptamer, H12 showed a basal PT value 
comparable to TBA, whereas, three modified aptamers, namely H3, H7 and H9, 
increased the basal PT value more efficiently than TBA (Figure 38). In the case of H3 
this result is more evident at the aptamer concentration of 10 M. The observed 
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trends in PT data suggests that, used in the plasma, H12 is as potent and efficient 
inhibitor as TBA, H3 is a more potent thrombin inhibitor than TBA, despite its efficiency 
is similar to that of TBA, whereas H7 and particularly H9, are both more potent and 
more efficient thrombin inhibitors.  
 
 
 
Figure 38. PT values of TBA and its modified analogues. ***= p<0.001 vs. vehicle, 
°=p<0.05, °°=p<0.01, °°°=p<0.001 vs. TBA (n=3). 
 
The apparent incoherence between fibrinogen and PT assays observed for some of our 
modified aptamers, was also previously reported for differently modified TBAs.121,139 
These data support the hypothesis that, in presence of other thrombin effectors 
and/or precursors, such as in the case of plasma tests, the clotting inhibitory activity of 
some modified TBAs couldn't be explained exclusively on the base of the competition 
between aptamer and fibrinogen for thrombin ABE 1. Taking into consideration also 
previous literature data,121,139 several factors could affect the aptamer anticoagulant 
activity in the plasma assay: 1) the intrinsic affinity of the aptamer to the thrombin ABE 
1 (as judged by the ability of the aptamer to compete with fibrinogen in the fibrinogen 
assay); 2) the recruitment of the aptamer by other plasma components that could 
decrease the concentration available to interact with the thrombin; 3) the presence in 
99 
 
plasma of other ligands and effectors able to bind thrombin, thus modifying its affinity 
for TBA. Then, although aptamers H3, H7, H9 and H12 have shown lower affinities to 
thrombin compared to TBA, their anticoagulant activities have come out similar (H12) 
or significantly improved (H3, H7, H9) probably as a result of the interference 
produced by other plasma components.  
 
5.2 CONCLUSIONS 
In conclusion, in this study the structural features of the hmU containing modified TBA 
were correlate with their ability to inhibit fibrin clot formation in two different tests, 
providing a better understanding on the biological properties of TBA. All modified TBA 
preserve the ability to fold in the antiparallel intramolecular quadruplex topology 
characteristic of the parent TBA. At the explored concentrations, aptamers H4 and H13 
have shown no antithrombin activities in the fibrinogen test, or strongly reduced 
anticoagulant activity in the PT test. On the other hand, the effect of the presence of 
the hmU residue in four modified aptamers, namely H3, H12, H7 and H9, have 
consisted in a partial loss of antithrombin activity in fibrinogen assay, thus confirming 
the crucial role of residues T3 and T12 and suggesting an active role also for the TGT 
loop of the quadruplex in thrombin interaction, in line with other 
investigations.121,122,139,142Interestingly, despite their sub-optimal affinities to thrombin, 
three modified aptamers (H3, H7 and H9) showed improved anticoagulant properties 
in PT test, thus reinforcing the hypothesis that other plasma components could play a 
role in the anticoagulant activity of TBA and its derivatives. 
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5.3 EXPERIMENTAL SECTION 
 
Oligonucleotides synthesis and purification 
The modified oligonucleotides reported in Table 1 were synthesized on a Millipore 
Cyclone Plus DNA synthesizer using solid phase -cyanoethyl phosphoramidite 
chemistry at 15 µmol scale. The synthesis of the suitably protected 5-hydroxymethyl-
2'-deoxyuridine-3'-phosphoramidite was performed following the synthetic strategy 
proposed by Conte et al.146 The oligomers were detached from the support and 
deprotected by treatment with concentrated aqueous ammonia at 55°C overnight. 
The combined filtrates and washings were concentrated under reduced pressure, 
dissolved in H2O, analyzed and purified by high-performance liquid chromatography on 
a Nucleogel SAX column (Macherey–Nagel, 1000-8/46), using buffer A: 20 mM 
NaH2PO4/Na2HPO4 aqueous solution (pH 7.0) containing 20% (v/v) CH3CN and buffer B: 
1 M NaCl, 20 mM NaH2PO4/Na2HPO4 aqueous solution (pH 7.0) containing 20% (v/v) 
CH3CN; a linear gradient from 0 to 100% B for 45 min and flow rate 1 ml/min were 
used. The fractions of the oligomers were collected and successively desalted by Sep-
pak cartridges (C-18). The isolated oligomers proved to be >98% pure by NMR. 
 
CD spectroscopy 
CD samples of modified oligonucleotides and their natural counterpart were prepared 
at a ODN concentration of 100 µM by using a potassium phosphate buffer (10 mM 
KH2PO4/K2HPO4, 70 mM KCl, pH 7.0) and submitted to the annealing procedure 
(heating at 90°C and slowly cooling at room temperature). CD spectra of all 
quadruplexes and CD melting curves were registered on a Jasco 715 CD 
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spectrophotometer. For the CD spectra, the wavelength was varied from 220 to 320 
nm at 100 nm min-1 scan rate, and the spectra recorded with a response of 16 s, at 2.0 
nm bandwidth and normalized by subtraction of the background scan with buffer. The 
temperature was kept constant at 5°C with a thermoelectrically-controlled cell holder 
(Jasco PTC-348). CD melting curves were registered as a function of temperature from 
5°C to 80°C for all quadruplexes at their maximum Cotton effect wavelengths. The CD 
data were recorded in a 0.1 cm pathlength cuvette with a scan rate of 0.5°C/min. 
 
NMR spectroscopy 
NMR samples were prepared at a concentration of about 3 mM, in 0.6 mL (H2O/D2O 
9:1 v/v), buffer solution having 10 mM KH2PO4/K2HPO4, 70 mM KCl and 0.2 mM EDTA 
(pH 7.0). All the samples were heated for 5-10 min at 80 °C and slowly cooled (10-12 h) 
to room temperature. The solutions were equilibrated for several weeks at 4 °C. The 
annealing process was assumed to be complete when 1H NMR spectra were 
superimposeable on changing time. NMR spectra were recorded with Varian Unity 
INOVA 700 MHz and Varian Unity INOVA 500 MHz spectrometers. 1D proton spectra of 
the sample in H2O were recorded using pulsed-field gradient DPFGSE for H2O 
suppression.133 1H-chemical shifts were referenced relative to external sodium 2,2-
dimethyl-2-silapentane-5-sulfonate (DSS). Pulsed-field gradient DPFGSE sequence was 
used for NOESY147 (180 ms and 80 ms mixing times) and TOCSY148 (120 ms mixing time) 
experiments in H2O. All experiments were recorded using STATES-TPPI procedure for 
quadrature detection.149 In all 2D experiments, the time domain data consisted of 
2048 complex points in t2 and 400-512 fids in t1 dimension. A relaxation delay of 1.2 s 
was used for all experiments 
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Molecular modelling 
The main conformational features of quadruplex adopted by H9 were explored by 
means of a molecular modelling study. The AMBER force field using AMBER 99 
parameter set was used.150 The initial coordinates for the starting model of H9 were 
taken from the NMR solution structure of the quadruplex d(GGTTGGTGTGGTTGG) 
(Protein Data Bank entry number 148D), with the first and best representative 
conformer of the twelve available ones submitted by Feigon et al.84 
The initial d(GGTTGGTGHGGTTGG) G-quadruplex model was built by replacing one 
hydrogen of the 5-methyl group of the thymine in the ninth position with a hydroxyl 
one, using the Biopolymer building tool of Discover. The calculations were performed 
using a distance-dependent macroscopic dielectric constant of 4r and an infinite cut-
off for non-bonded interactions to partially compensate for the lack of solvent used.151 
Using the steepest descent followed by quasi-Newton-Raphson method (VA09A), the 
conformational energy of the complex was minimized until convergence to an RMS 
gradient of 0.1 kcal/mol Å was reached. Illustrations of the structure were generated 
using the INSIGHT II program, version 2005 (Accelrys, San Diego, CA, USA). All the 
calculations were performed on a PC running Linux ES 2.6.9. 
 
Fibrinogen Assay 
The fibrinogen clotting times were measured spectrophotometrically. ODNs were 
incubated for 1 min at 37 °C in 1.0 mL of PBS  containing 2.0 mg/mL of fibrinogen 
(Fibrinogen from human plasma, F 3879, Sigma-Aldrich) in a PMMA cuvette (vol. 1.5 
mL, c.o. 1 cm, Brand). 100 μL of human thrombin (10 NIH per mL; Sigma-Aldrich, 
T8885, human thrombin suitable for thrombin time test) was then added to the 
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solution containing the fibrinogen and the ODN. The time required to fibrin 
polymerization was determined from UV scattering curve, registered as a function of 
the time (wavelength fixed at 380 nm) in the presence of each ODN. Each curve was 
determined in triplicate at different concentrations. The clotting time value reported 
as M ± SE, was derived as the maximum of the second derivative of each scattering 
curve. The basal clotting time was determined by measuring the UV scattering as a 
function of the time produced in the absence of any ODN. In the absence of any 
inhibitor, the clotting time value was 25.6 ± 1.5 s. The prolonged fibrinogen clotting 
times of TBA and modified ODNs were calculated by subtracting the basal clotting time 
produced by thrombin from that measured in the presence of the aptamer. 
 
PT assay 
PT assay on human plasma samples was measured by using Koagulab MJ Coagulation 
System with a specific kit HemosIL RecombinPlasTin 2G (Instrumentation Laboratory, 
Milan, Italy). Briefly, this method relies on the high sensitivity of thromboplastin 
reagent based on recombinant human tissue factors. The addiction of recombiplastin 
to the plasma, in presence of calcium ions, initiates the activation of extrinsic pathway 
converting the fibrinogen into fibrin, with a formation of solid gel. The procedure was 
according to the manufacturer's instructions. In our experimental conditions, each 
ODN or vehicle was incubated with 100 µL of plasma at 37°C for 15 minutes, after that 
200 µL of the kit solution containing recombiplastin was added with consequent 
activation of extrinsic pathway. For the evaluation of PT at 20 µM, in the apposite 
microtube, 2 µL of the corresponding ODN solution (1 mM in PBS) or vehicle was 
added. The PT at final ODN concentration of 10 µM and 2 µM was determined using 2 
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µL of a diluted solution (0.5 mM and 0.1 mM ODN solution in PBS, respectively). The PT 
measurement was produced in triplicate and the average and its standard error values 
were calculated and expressed as seconds. The basal clotting time was determined by 
measuring the clotting time in absence of any ODN. 
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6. Expanding the Potential of G-Quadruplex Structures: 
Formation of a Heterochiral TBA Analogue 
 
Oligonucleotides containing L residues (both homo- and heterochirals equences) are 
endowed with interesting properties and have been exploited for the development of 
various tools and devices such as aptamers,152molecular beacons153and microarrays.154 
Although the capacity of oligonucleotides containing L-residues to form duplex 
structures has been investigated since 1991,154the prospect that this type of 
oligonucleotide is able to fold also into stable G-quadruplexes (as well as theproperties 
of these structures and their potential application) has been explored only in recent 
years. For example, L-homochiral and -heterochiral tetramolecular G-quadruplex 
structures based on the sequence TGGGGT have been prepared, and their structural 
properties have been investigated.155,156Recently, new dynamic properties of G-
quadruplex structures have come to light through the investigation of a heterochiral 
TGGGGT analogue that contains a 5’–5’ polarity inversion site in the G-run centre.157 
As the most important property of oligonucleotides containing L-residues is their 
resistance to nucleases, biologically significant L-homochiral monomolecular G-
quadruplexes have also been studied. For example, Urata et al. described the anti-HIV-
1 activity of a G-quadruplex forming a L-17-mer aptamer that targets the viral gp120 
envelope protein.158Interestingly, the peroxidase DNAzyme properties of a G-
quadruplex that forms another L-17-mer have also been reported. Although TBA was 
first discovered as an anticoagulant agent, its potential applications have been 
expanded by the design and preparation of molecular sensors for thrombin, K+ions159 
and, recently, for the detection of Pb++ and Hg++ in human serum.160As it is evident that 
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the applications of this sequence would benefit from increased stability in biological 
environments, we addressed the question of whether heterochiral analogues of TBA 
are able to form stable G-quadruplex structures. The investigated analogues of TBA are 
listed in Table 12.  
 
 
 
 
 
 
 
[a] L residues are in lower case. 
 
Table 12. Sequences investigated and melting temperatures 
 
A common feature in all the sequences is the use of only L residues for the guanosines 
in G-tetrads. The reasons for this preference are: 1) to maintain the same type of 
chirality for the scaffold, that is, the part of the molecule mostly responsible for both 
G-quadruplex structural stability and ion binding, and 2) to place L-residues at the ends 
of the sequences to make the random coil (in equilibrium with the folded structure) 
resistant to exonucleases, which are ubiquitous in biological systems. 
 
 
 
 
NAME SEQUENCE 5’ 3’[a] Tm[C°] 
D12 
D23 
D13 
D123 
L-TBA 
TBA 
ggTTggTGTggttgg 
ggttggTGTggTTgg 
ggTTggtgtggTTgg 
ggTTggTGTggTTgg 
GGTTGGTGTGGTTGG 
ggttggtgtggttgg 
36 
36 
52 
37 
50 
50 
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6.1 RESULTS AND DISCUSSION 
Heterochiral oligodeoxynucleotides (ODNs) were first investigated by CD to test their 
ability to fold into G-quadruplexes and, in particular, to adopt a conformation similar 
to that of TBA. ODNs D12, D123 and D23 showed comparable CD profiles (Figure39): 
characterized by two positive bands (~236 and 280 nm) and two negative bands (~260 
and 298 nm).  
 
Figure 39.CD spectra at 20°C of TBA (black), D12 (red), D23 (green), D123 (blue) recorded in a 
0.1 cm pathlength cuvette at 100 µM ODN strand concentration in a buffer 10 mM 
KH2PO4/K2HPO4, 70 mM KCl (pH 7.0). 
 
Although their CD spectra suggest the presence of G-quadruplex structures, a 
comparison of their profiles with those of L-TBA and TBA does not support formation 
of the antiparallel structure typical of the aptamer. In contrast, the CD profile of D13 
showed positive bands at ~230and 268 nm and negative bands at ~247 and 294 nm 
(Figure40 A). Straightforward comparison of the CD spectra of D13,l-TBA and TBA 
strongly suggested that D13 folds similarly tol-TBA (the mirror image of natural TBA) 
and, apart from handedness, to TBA itself. Useful information was also obtained from 
CD melting/annealing profiles (estimated melting temperatures in Table 12). ODNs 
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D12, D123 and D23showed values around 36–37°C, whereas D13 exhibited the highest 
thermal stability (52 °C; slightly higher than that of the natural TBA; Figure 40B). Most 
importantly, the melting/annealing profiles of D13 do not show a noticeable 
hysteresis, a feature common to the other heterochiral ODNs investigated here. Taken 
together, the data suggest the presence of a monomolecular structure only in the case 
of D13. 
 
 
 
Figure 40. A) CD spectra at 20°C of TBA (red line), L-TBA (blue line) and D13 (green line); B) CD 
melting curves of TBA (red line) and D13 (green line). See experimental section for details. 
 
In order to confirm this, PAGE was performed (Figure 41). The electrophoretic motility 
of D13 was the same as that of TBA and its mirror-image (L-TBA), thus corroborating 
the CD melting data that suggested a monomolecular G-quadruplex structure. 
In contrast, the bands corresponding to D12, D123 and D23 showed lower motility 
than those for D13, TBA and L-TBA and appeared quite smeared, thus confirming the 
presence of multimolecular structures. Close behavior al similarities between D12, 
D123 and D23 on the one hand, and between D13, TBA and L-TBA on the other were 
also evident in the 1H NMR spectra (Figure 42).  
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Figure 41. Non-denaturing PAGE. Samples were loaded on a non-denaturing gel, run at 15°C. 
Oligonucleotides were revealed by UV shadowing. See text and the experimental section for 
details. 
 
In fact, D13, TBA and L-TBA showed imino proton signals (diagnostic for G-tetrads 
formation) ranging from 11.8 to 12.3 ppm, whereas in the case of D12, D123 and D23, 
the same signals were spread over a broader spectral region (10.4–12.3 ppm) and, in 
some cases, appeared larger and with more than the expected eight signals. As the 
data from the different techniques clearly indicated that only D13 folds similarly to 
TBA, thus the attention was focused on this ODN for in-depth NMR investigations. 
The simple 1D spectrum for this ODN indicates that, under the conditions used, it 
forms mainly a single well-defined hydrogen-bonded conformation. In fact, the 1H 
NMR spectrum(700 MHz, T=258C) shows the presence of eight well-defined signals in 
the region 11.8–12.3 ppm, attributable to imino protons involved in Hoogsteen 
hydrogen bonds of at least two G-quartets, and 15 signals in the aromatic region from 
nine guanine H8 and six thymine H6 protons. 
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Figure 42. 1H NMR spectra (aromatic and imino proton regions, 700 MHz, T=258°C) of the 
ODNs (see Table 12). 
 
 
 
111 
 
Combined analysis of 2D NOESY (Figures 43) and TOCSY spectra (data notshown) 
allowed us to determine almost completely the assignment of the nonexchangeable 
protons (Table 13). The intensities of NOESY crosspeaks between the H8 proton bases 
and  sugar H1’ resonances indicate that four (G1, G5, G10, G14) out of nine G residues 
of D13 adopt a syn glycosidic conformation, for which the H8 resonances of syn G 
residues. The stability of D13 in a biological environment was tested by a degradation 
assay in foetal bovine serum (Figure 44) and gel electrophoresis. The results clearly 
indicate that, underthese conditions, D13 is resistant to nucleases up to 24 h,whereas 
its natural counterpart (TBA) is mostly degraded by 1h.116 
 
 
 
 
 
 
 
 
 
 
 
 
Table 13. Proton chemical shifts assignment for G-quadruplex formed by ODN D13  (700 MHz, T 
= 25°C) in 10 mM KH2PO4/K2HPO4, 70 mM KCl and 0.2 mM EDTA (pH 7.0). N.D. = not 
determined 
 
D135'-GL1GL2TD3TD4GL5GL6TL7GL8TL9GL10GL11TD12TD13GL14GL15-3' 
 H8/H6 H1' H2'/H2'' H3' H4' H5'/H5'' CH3 
GL1 7.44 6.05 2.93 4.88 4.39 N.D. - 
GL2 7.90 5.94 2.83/2.96 5.04 4.40 N.D. - 
TD3 7.84 6.38 2.35/2.58 4.73 4.50 N.D. 1.95 
TD4 7.45 5.94 1.84/2.15 4.73 4.40 4.02 1.59 
GL5 7.43 6.04 2.88/3.57 4.83 4.39 4.25/4.13 - 
GL6 7.65 5.90 2.59/2.74 5.09 4.23 N.D. - 
TL7 7.86 6.42 2.47/2.59 4.82 4.41 4.25/4.13 1.96 
GL8 7.42 5.77 1.97/2.33 4.82 3.99 N.D. - 
TL9 7.27 5.82 1.92/2.38 4.62 3.75 3.56/2.99 1.78 
GL10 7.47 6.03 2.87/3.68 4.84 4.23 4.11 - 
GL11 7.89 5.92 2.32/2.77 5.03 4.22 4.16/4.01 - 
TD12 7.84 6.38 2.35/2.58 4.73 4.51 4.17 1.95 
TD13 7.45 5.94 1.84/2.18 4.73 4.40 4.01 1.59 
GL14 7.48 6.07 2.94/3.62 4.88 4.51 4.17 - 
GL15 7.98 6.10 2.41/2.66 4.78 4.25 N.D. - 
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Figure 43: Expanded 2D NOESY spectrum of D13 (700 MHz; 25°C; strand concentration 3 mM; 
10 mM KH2PO4/K2HPO4, 70 mM KCl and 0.2 mM EDTA, pH 7.0 in H2O/D2O 9:1; total volume 0.6 
ml; mixing time 180 ms) correlating aromatic base protons and sugar protons. 
 
 
 
 
Figure 44. Stability of D13 in 10% foetal bovine serum (FBS), as monitored by denaturing PAGE 
(time points shown in the figure). See the Experimental Section for details. 
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6.2 CONCLUSIONS 
In summary, we have shown that heterochiral ODNs based on the sequence of TBA are 
able to fold into G-quadruplex structures. In particular, taken together the data for D13 
indicate that, apart from handedness, this ODN folds into the “chair-like” G-quadruplex 
conformation (typical of TBA), yet it exhibits slightly higher thermal stability. 
Furthermore, ODN D13 has been shown, by its resistance to both exonucleases and 
endonucleases, to survive in a biological environment. It should be noted that in the G-
quadruplex formed by D13, the two TT loops are composed of natural d-thymines 
(these residues are mostly responsible for the binding to thrombin).100, 159 
These properties are particularly important for the potential applications of D13 as an 
ion sensor in biological fluids and as an anticoagulant agent. Furthermore, from several 
structural investigations of TBA, it is well known that the central TGT loop makes a 
remarkable contribution to the thermal stability of the antiparallel quadruplex 
structure adopted by the aptamer. 100, 159 It is noteworthy that, of the heterochiral 
ODNs investigated,D13 is the only one in which the guanines involved in G-tetrads 
formation and the residues of the central TGT loop share the same configuration (l). It 
is likely that this peculiar feature protects the structure from severe conformationalc 
hanges that could reduce thermal stability and induce formation of less-stable 
structures. 
Recently, G-quadruplex structures have been used as catalysts for enantioselective 
Friedel–Crafts161and Diels–Alder reactions.162,163The discovery that heterochiral ODNs 
are able to form stable G-quadruplex structures also opens new possibilities in this 
research area, by adding a further approach to improve stereocontrol and expand 
substrate variety. 
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6.3 EXPERIMENTAL SECTION 
 
Oligonucleotides synthesis and purification 
All the oligonucleotides were synthesized on a Millipore Cyclone Plus DNA synthesizer 
using solid phase β-cyanoethyl phosphoramidite chemistry at 15 μmol scale. The 
synthesis were performed by using normal 3’-phosphoramidites and 5’-
dimethoxytrityl-β-L-deoxyguanosine (iBu)-3’-phosphoramidite and 5’-dimethoxytrityl-
β-L-deoxythymidine-3’-phosphoramidite. For all ODNs an universal support was used. 
The oligomers were detached from the support and deprotected by treatment with 
concentrated aqueous ammonia at 80°C overnight. The combined filtrates and 
washings were concentrated under reduced pressure, redissolved in H2O, analyzed and 
purified by high-performance liquid chromatography on a Nucleogel SAX column 
(Macherey–Nagel, 1000-8/46), using buffer A: 20mM KH2PO4/K2HPO4 aqueous solution 
(pH 7.0) containing 20% (v/v) CH3CN and buffer B: 1 M KCl, 20mM KH2PO4/K2HPO4 
aqueous solution (pH 7.0) containing 20% (v/v) CH3CN; a linear gradient from 0 to 
100% B for 45 min and flow rate 1 ml/min were used. The fractions of the oligomers 
were collected and successively desalted by Sep-pak cartridges (C-18). The isolated 
oligomers proved to be >98% pure by NMR. 
 
CD spectroscopy 
CD samples were prepared at a concentration of 1x10-4M by using a buffer solution: 10 
mM KH2PO4/K2HPO4, 70 mM KCl (pH 7.0). CD data of all quadruplexes were registered 
on a Jasco 715 CD spectrophotometer in a 0.1 cm pathlength cuvette. For the CD 
spectra, the wavelength was varied from 220 to 320 nm at 100 nm min-1 scan rate, 
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and the spectra recorded with a response of 16 s, at 2.0 nm bandwidth and normalized 
by subtraction of the background scan with buffer. The temperature was kept constant 
at 20°C with a thermoelectrically-controlled cell holder (Jasco PTC-348). CD melting 
and annealing curves were registered as a function of temperature from 20°C to 80°C 
at 294 nm for TBA and D13, at 260 nm for all the other quadruplexes with a scan rate 
of 10°C/h.  
 
Gel electrophoresis 
All oligonucleotides were analyzed by non-denaturing PAGE. Samples in the NMR 
buffer (20 mM KH2PO4, 70 mM KCl and 0.2 mM EDTA, pH=7) were loaded on a 20% 
polyacrylamide gel containing Tris–Borate-EDTA (TBE) 2.5x and KCl 50 mM. The run 
buffer was TBE 1x containing 100 mM KCl. For all samples, a solution of glycerol/TBE 
1x-100mM KCl 2:1 was added just before loading. Electrophoresis was performed at 
9.2 V/cm at a temperature close to 10°C. Bands were visualized by UV shadowing. 
 
Nuclear magnetic resonance experiments  
NMR samples were prepared at a concentration of about 3 mM, in 0.6 mL (H2O/D2O 
9:1 v/v), buffer solution having 10 mM KH2PO4/K2HPO4, 70 mM KCl and 0.2 mM EDTA 
(pH 7.0). All the samples were heated for 5-10 min at 80°C and slowly cooled (10-12 h) 
to room temperature. The solutions were equilibrated for several weeks at 4°C. The 
annealing process was assumed to be complete when 1H NMR spectra were 
superimposeable on changing time. NMR spectra were recorded with a Varian Unity 
INOVA 700 MHz spectrometer. 1D proton spectra of the samples in H2O were 
recorded using pulsed-field gradient DPFGSE for H2O suppression. 
1H-chemical shifts 
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were referenced relative to external sodium 2,2-dimethyl-2-silapentane-5-sulfonate 
(DSS). Pulsed-field gradient DPFGSE sequence was used for NOESY (180 and 80 ms 
mixing times) and TOCSY (120 ms mixing time) experiments in H2O (700 MHz, T = 
25°C). The experiments were recorded using STATES-TPPI procedure for quadrature 
detection. In the 2D experiments, the time domain data consisted of 4096 complex 
points in t2 and 256-512 fids in t1 dimension. A relaxation delay of 1.5 s was used for 
the experiments. 
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